Bortezomib (PS-341)

Catalog No.S1013 Synonyms: LDP-341, MLM341

Molecular Weight(MW): 384.24

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with K_i of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.

Cited by 379 Publications

Nature, 2019, 567(7747):262-266

PubMed: 30842662 ( click the link to review the publication )

Science, 2019, 363(6429)

PubMed: 30792274 ( click the link to review the publication )

Cell, 2019, 178(2):361-373

PubMed: 31204100 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Cell, 2019, 35(1):46-63

PubMed: 30581152 ( click the link to review the publication )

Nature, 2018, 560(7718):325-330

PubMed: 30089904 ( click the link to review the publication )

Nature, 2017, 550(7677):534-538

PubMed: 29045385 ( click the link to review the publication )

Science, 2017, eaal3755

PubMed: 28302793 ( click the link to review the publication )

Science, 2017, eaal3755

PubMed: 28302793 ( click the link to review the publication )

Cell, 2017, 171(5):1094-1109

PubMed: 29149604 ( click the link to review the publication )

Cancer Discov, 2017, 7(3):302-321

PubMed: 28108460 ( click the link to review the publication )

Cancer Cell, 2017, 32(6):748-760

PubMed: 29232553 ( click the link to review the publication )

Nat Med, 2014, 20(6):599-606

PubMed: 24813251 ( click the link to review the publication )

Cell Stem Cell, 2012, 11(2):242-52

PubMed: 22862949 ( click the link to review the publication )

Nat Chem Biol, 2019, 15(3):232-240

PubMed: 30692684 ( click the link to review the publication )

Nat Commun, 2019, 10(1):273

PubMed: 30655516 ( click the link to review the publication )

Sci Adv, 2019, 5(2):eaau7130

PubMed: 30775435 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(10):e9930

PubMed: 31476112 ( click the link to review the publication )

Leukemia, 2019, 10.1038/s41375-019-0525-6

PubMed: 31358854 ( click the link to review the publication )

Leukemia, 2019, 33(1):171-180

PubMed: 30026574 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472

PubMed: 31138526 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472

PubMed: 31484670 ( click the link to review the publication )
Haematologica, 2019, 10.3324/haematol.2018.212266

PubMed: 31101754 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):28

PubMed: 30717817 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472

PubMed: 31142515 ( click the link to review the publication )

Cancer Res, 2019, 79(21):5536-5549

PubMed: 31530568 ( click the link to review the publication )

Cell Rep, 2019, 27(6):1657-1665

PubMed: 31067453 ( click the link to review the publication )

J Control Release, 2019, 306:149-164

PubMed: 31121280 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32615

PubMed: 31390487 ( click the link to review the publication )

Am J Transplant, 2019, 19(3):724-736

PubMed: 30102844 ( click the link to review the publication )

Cancer Lett, 2019, 442:233-241

PubMed: 30419344 ( click the link to review the publication )

Cancers (Basel), 2019, 11(7)

PubMed: 31315220 ( click the link to review the publication )

PLoS Pathog, 2019, 15(1):e1007498

PubMed: 30645648 ( click the link to review the publication )

Cell Death Dis, 2019, 10(10):781

PubMed: 31611552 ( click the link to review the publication )

Cell Death Dis, 2019, 10(5):342

PubMed: 31019203 ( click the link to review the publication )

Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.06.006

PubMed: 31303577 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(7):1205-1216

PubMed: 31092565 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-18-1319

PubMed: 31594826 ( click the link to review the publication )

Hum Mutat, 2019, 40(4):392-403

PubMed: 30609140 ( click the link to review the publication )

Mol Oncol, 2019, 13(2):290-306

PubMed: 30422399 ( click the link to review the publication )

Aging (Albany NY), 2019, 11(11):3624-3638

PubMed: 31170093 ( click the link to review the publication )

Mol Neurobiol, 2019, 56(3):1653-1664

PubMed: 29916141 ( click the link to review the publication )

Neoplasia, 2019, 21(7):653-664

PubMed: 31132676 ( click the link to review the publication )

Oxid Med Cell Longev, 2019, 2019:1659468

PubMed: 31281566 ( click the link to review the publication )

Eur J Med Chem, 2019, 166:65-74

PubMed: 30684871 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(8):1622-1634

PubMed: 31497346 ( click the link to review the publication )
Biochim Biophys Acta Mol Cell Res, 2019, 1866(10):1544-1555

PubMed: 31326539 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2019, 1866(2):252-263

PubMed: 30445147 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786.MCR-18-1332

PubMed: 31043489 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786

PubMed: 31540997 ( click the link to review the publication )

ACS Chem Biol, 2019, 10.1021/acschembio-00191

PubMed: 31243962 ( click the link to review the publication )

Front Oncol, 2019, 9:958

PubMed: 31632904 ( click the link to review the publication )

Front Oncol, 2019, 9:722

PubMed: 31440466 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(8):5390-5402

PubMed: 31140729 ( click the link to review the publication )

Mol Biol Cell, 2019, 30(7):838-850

PubMed: 30865564 ( click the link to review the publication )

Arthritis Res Ther, 2019, 21(1):50

PubMed: 30728075 ( click the link to review the publication )

Talanta, 2019, 199:32-39

PubMed: 30952265 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(3)

PubMed: 30736330 ( click the link to review the publication )

Apoptosis, 2019, 24(5-6):404-413

PubMed: 30997620 ( click the link to review the publication )

J Biol Chem, 2019, 294(40):14562-14573

PubMed: 31371451 ( click the link to review the publication )

Food Chem Toxicol, 2019, 131:110537

PubMed: 31150782 ( click the link to review the publication )

Apoptosis, 2019, 24(1-2):184-197

PubMed: 30498998 ( click the link to review the publication )

Gene, 2019, 707:86-92

PubMed: 31071385 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:8711-8720

PubMed: 31576173 ( click the link to review the publication )

Int J Oncol, 2019, 55(2):499-512

PubMed: 31268156 ( click the link to review the publication )

Cell Signal, 2019, 62:109351

PubMed: 31260799 ( click the link to review the publication )

J Cell Biochem, 2019, 120(3):3243-3258

PubMed: 30362618 ( click the link to review the publication )

Biochimie, 2019, 162:46-54

PubMed: 30946948 ( click the link to review the publication )

Oncol Rep, 2019, 42(1):35-42

PubMed: 31115546 ( click the link to review the publication )

Oncol Rep, 2019, 41(3):1678-1690

PubMed: 30664164 ( click the link to review the publication )
Biochem Biophys Res Commun, 2019, 514(4):1140-1146

PubMed: 31103265 ( click the link to review the publication )

Leuk Lymphoma, 2019, 10.1080/10428194.2019.1616190

PubMed: 31111763 ( click the link to review the publication )

Leuk Res, 2019, 78:12-20

PubMed: 30660961 ( click the link to review the publication )

Naunyn Schmiedebergs Arch Pharmacol, 2019, 392(4):461-466

PubMed: 30554340 ( click the link to review the publication )

Methods Enzymol, 2019, 619:145-159

PubMed: 30910019 ( click the link to review the publication )

J Blood Med, 2019, 10:105-109

PubMed: 31043801 ( click the link to review the publication )

Oncotarget, 2019, 10(28):2709-2721

PubMed: 31105871 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2019, 1863(6):1108-1115

PubMed: 30974160 ( click the link to review the publication )

J Clin Invest, 2018, 128(7):2877-2893

PubMed: 29863498 ( click the link to review the publication )

Leukemia, 2018, 32(1):139-148

PubMed: 28663576 ( click the link to review the publication )

Cancer Res, 2018, 78(5):1155-1168

PubMed: 29259009 ( click the link to review the publication )

Kidney Int, 2018, 93(3):670-680

PubMed: 29229189 ( click the link to review the publication )

Blood Cancer J, 2018, 8(11):105

PubMed: 30409995 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2018, 10(26):21825-21835

PubMed: 29897225 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):29

PubMed: 29482577 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):112

PubMed: 30180865 ( click the link to review the publication )

Cancer Lett, 2018, 420:156-167

PubMed: 29410067 ( click the link to review the publication )

Sci Signal, 2018, 11(549)

PubMed: 30254057 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(7):1416-1429

PubMed: 29703842 ( click the link to review the publication )

J Mol Cell Cardiol, 2018, 116:16-28

PubMed: 29371135 ( click the link to review the publication )

Mol Oncol, 2018, 12(12):2124-2135

PubMed: 30259640 ( click the link to review the publication )

J Cell Physiol, 2018, 233(5):4258-4271

PubMed: 29057477 ( click the link to review the publication )

Lab Invest, 2018, 98(6):708-714

PubMed: 29540860 ( click the link to review the publication )

Biochem Pharmacol, 2018, 156:291-301

PubMed: 30149015 ( click the link to review the publication )
J Ethnopharmacol, 2018, 220:220-227

PubMed: 29097252 ( click the link to review the publication )

Exp Cell Res, 2018, 369(1):120-128

PubMed: 29772221 ( click the link to review the publication )

Int Immunopharmacol, 2018, 54:39-45

PubMed: 29100036 ( click the link to review the publication )

Mol Cells, 2018, 41(12):1008-1015

PubMed: 30396235 ( click the link to review the publication )

Oncol Rep, 2018, 39(6):2873-2880

PubMed: 29693175 ( click the link to review the publication )

Oncol Rep, 2018, 40(6):3714-3724

PubMed: 30272343 ( click the link to review the publication )

Eur J Pharmacol, 2018, 830:17-25

PubMed: 29680228 ( click the link to review the publication )

Oncol Res, 2018, 26(3):421-429

PubMed: 28899456 ( click the link to review the publication )

Dis Markers, 2018, 2018:3810108

PubMed: 30647797 ( click the link to review the publication )

Dis Markers, 2018, 2018:3810108

PubMed: 30647797 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 501(1):286-292

PubMed: 29729272 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 505(1):126-133

PubMed: 30236985 ( click the link to review the publication )

J Bone Miner Metab, 2018, 36(5):537-546

PubMed: 29027021 ( click the link to review the publication )

Ann Diagn Pathol, 2018, 32:28-34

PubMed: 29414394 ( click the link to review the publication )

Target Oncol, 2018, 13(6):779-793

PubMed: 30446871 ( click the link to review the publication )

Viruses, 2018, 10(10)

PubMed: 30261679 ( click the link to review the publication )

Oncotarget, 2018, 9(23):16521-16532

PubMed: 29662664 ( click the link to review the publication )

Oncotarget, 2018, 9(5):6450-6462

PubMed: 29464084 ( click the link to review the publication )

Oncotarget, 2018, 9(5):6450-6462

PubMed: 29464084 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1692

PubMed: 29167449 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(4):1012-1024

PubMed: 28151717 ( click the link to review the publication )

Leukemia, 2017, 31(7):1570-1581

PubMed: 27890927 ( click the link to review the publication )

Cancer Immunol Res, 2017, 5(10):839-846

PubMed: 28903971 ( click the link to review the publication )

Cancer Res, 2017, 77(22):6282-6298

PubMed: 28978635 ( click the link to review the publication )
Cancer Res, 2017, 77(11):2927-2937

PubMed: 28404587 ( click the link to review the publication )

Cell Mol Immunol, 2017, 10.1038/cmi.2017.8

PubMed: 28690324 ( click the link to review the publication )

Genomics Inform, 2017, 15(3):87-97

PubMed: 29020724 ( click the link to review the publication )

Cancer Lett, 2017, 405:63-72

PubMed: 28716527 ( click the link to review the publication )

J Pathol, 2017, 241(4):534-546

PubMed: 27976373 ( click the link to review the publication )

Cell Death Dis, 2017, 8(2):e2585

PubMed: 28151478 ( click the link to review the publication )

Exp Mol Med, 2017, 49(8):e365

PubMed: 28798402 ( click the link to review the publication )

J Cancer, 2017, 8(5):839-851

PubMed: 28382147 ( click the link to review the publication )

Epigenetics, 2017, 12(2):105-112

PubMed: 27935420 ( click the link to review the publication )

Biochem Pharmacol, 2017, 143:118-128

PubMed: 28642038 ( click the link to review the publication )

Sci Rep, 2017, 7:44700

PubMed: 28304377 ( click the link to review the publication )

Am J Pathol, 2017, 187(12):2775-2787

PubMed: 28919113 ( click the link to review the publication )

J Biol Chem, 2017, 292(28):11970-11979

PubMed: 28588027 ( click the link to review the publication )

Endocrinology, 2017, 158(10):3097-3108

PubMed: 28938421 ( click the link to review the publication )

Biomed Pharmacother, 2017, 88:562-568

PubMed: 28131096 ( click the link to review the publication )

BMC Genomics, 2017, 18(1):127

PubMed: 28166733 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(1):20-34

PubMed: 28760737 ( click the link to review the publication )

Cell Signal, 2017, 32:124-132

PubMed: 28161489 ( click the link to review the publication )

Mol Brain, 2017, 10(1):7

PubMed: 28196470 ( click the link to review the publication )

Life Sci, 2017, 173:36-42

PubMed: 28212825 ( click the link to review the publication )

BMC Cancer, 2017, 17(1):366

PubMed: 28545541 ( click the link to review the publication )

Neurotox Res, 2017, 32(4):555-562

PubMed: 28612296 ( click the link to review the publication )

Transl Oncol, 2017, 10(4):632-640

PubMed: 28668761 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 488(2):400-406

PubMed: 28502636 ( click the link to review the publication )
Leuk Lymphoma, 2017, 58(12):2916-2925

PubMed: 28509582 ( click the link to review the publication )

Cancer Genomics Proteomics, 2017, 14(1):35-51

PubMed: 28031236 ( click the link to review the publication )

Oncol Lett, 2017, 13(2):647-654

PubMed: 28356941 ( click the link to review the publication )

Cancer Metab, 2017, 5:7

PubMed: 28855983 ( click the link to review the publication )

Oncotarget, 2017, 8(34):57047-57057

PubMed: 28915653 ( click the link to review the publication )

Cell, 2017, 170(5):860-874

PubMed: 28803730 ( click the link to review the publication )

Oncotarget, 2017, 8(70):114698-114709

PubMed: 29383113 ( click the link to review the publication )

Cell, 2017, 169(6):1105-1118

PubMed: 28575672 ( click the link to review the publication )

Sci Rep, 2017, 7(1):682

PubMed: 28386133 ( click the link to review the publication )

Sci Transl Med, 2016, 8(339):339ra70

PubMed: 27194728 ( click the link to review the publication )

Hepatology, 2016, 64(1):161-74

PubMed: 26926206 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Leukemia, 2016, 30(4):861-72

PubMed: 26658839 ( click the link to review the publication )

Cancer Res, 2016, 76(12):3531-40

PubMed: 27197154 ( click the link to review the publication )

Matrix Biol, 2016, 55:22-34

PubMed: 27016342 ( click the link to review the publication )

Blood Cancer J, 2016, 6(7):e446

PubMed: 27421095 ( click the link to review the publication )

Blood Cancer J, 2016, 6(8):e462

PubMed: 27564460 ( click the link to review the publication )

Oncogene, 2016, 35(38):4973-80

PubMed: 26973240 ( click the link to review the publication )

Cancer Lett, 2016, 372(1):82-8

PubMed: 26721204 ( click the link to review the publication )

J Exp Clin Cancer Res, 2016, 35:52

PubMed: 27009084 ( click the link to review the publication )

Lab Chip, 2016, 16(2):334-44

PubMed: 26660268 ( click the link to review the publication )

FASEB J, 2016, 30(2):923-32

PubMed: 26546130 ( click the link to review the publication )

Expert Opin Drug Deliv, 2016, 13(8):1075-81

PubMed: 27087021 ( click the link to review the publication )

Br J Haematol, 2016, 173(1):70-81

PubMed: 26729247 ( click the link to review the publication )
Mol Biol Cell, 2016, 27(8):1272-85

PubMed: 26941331 ( click the link to review the publication )

Am J Pathol, 2016, 186(3):678-90

PubMed: 26801735 ( click the link to review the publication )

J Biol Chem, 2016, 291(2):939-47

PubMed: 26527686 ( click the link to review the publication )

J Biol Chem, 2016, 291(29):15082-92

PubMed: 27226596 ( click the link to review the publication )

Int J Oncol, 2016, 49(5):1848-1858

PubMed: 27601063 ( click the link to review the publication )

Eur J Pharmacol, 2016, 791:99-104

PubMed: 27568836 ( click the link to review the publication )

Eur J Cell Biol, 2016, 95(10):389-400

PubMed: 27567537 ( click the link to review the publication )

PLoS One, 2016, 11(12):e0168193

PubMed: 27978543 ( click the link to review the publication )

PLoS One, 2016, 11(3):e0150484

PubMed: 26930278 ( click the link to review the publication )

Leuk Lymphoma, 2016, 57(7):1677-86

PubMed: 26421357 ( click the link to review the publication )

Leuk Lymphoma, 2016, 57(11):2644-52

PubMed: 26980288 ( click the link to review the publication )

Anticancer Res, 2016, 36(4):1673-82

PubMed: 27069145 ( click the link to review the publication )

Target Oncol, 2016, 11(6):783-798

PubMed: 27250763 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2016, 95(2):751-60

PubMed: 27045812 ( click the link to review the publication )

Sarcoma, 2016, 2016:3484673

PubMed: 27822137 ( click the link to review the publication )

Oncotarget, 2016, 7(4):4454-67

PubMed: 26683357 ( click the link to review the publication )

Drug Discov Ther, 2016, 10(4):195-200

PubMed: 27594296 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71790-71801

PubMed: 27708243 ( click the link to review the publication )

Oncotarget, 2016, 7(47):77622-77634

PubMed: 27769058 ( click the link to review the publication )

Oncotarget, 2016, 7(2):1598-607

PubMed: 26624982 ( click the link to review the publication )

Oncotarget, 2016, 7(29):45214-45224

PubMed: 27286258 ( click the link to review the publication )

Oncotarget, 2016, 7(4):4559-69

PubMed: 26683226 ( click the link to review the publication )

Oncotarget, 2016, 7(11):12254-66

PubMed: 26930721 ( click the link to review the publication )

Oncotarget, 2016, 7(43):70845-70856

PubMed: 27683126 ( click the link to review the publication )
Mol Cells, 2016, 39(12):898-908

PubMed: 28008160 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-1462

PubMed: 25748087 ( click the link to review the publication )

Leukemia, 2015, 29(6):1390-401

PubMed: 25533804 ( click the link to review the publication )

Cancer Res, 2015, 10.1158/0008-5472.CAN-14-2109

PubMed: 25712341 ( click the link to review the publication )

Biomaterials, 2015, 73:70-84

PubMed: 26402156 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )

J Control Release, 2015, 211:44-52

PubMed: 26031842 ( click the link to review the publication )

Elife, 2015, 4:e08153

PubMed: 26327694 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2014.455

PubMed: 25619841 ( click the link to review the publication )

Oncogene, 2015, 34(16):2138-2144

PubMed: 24909167 ( click the link to review the publication )

Cancer Lett, 2015, 10.1016/j.canlet.2015.02.044

PubMed: 25737303 ( click the link to review the publication )

Br J Haematol, 2015, 171(4):595-605

PubMed: 26310606 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(2):639-50

PubMed: 25973303 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(2):223-30

PubMed: ( click the link to review the publication )

J Immunol, 2015, 194(4):1695-701

PubMed: 25560410 ( click the link to review the publication )

Traffic, 2015, 10.1111/tra.12287

PubMed: 25824657 ( click the link to review the publication )

J Virol, 2015, 89(5):2643-58

PubMed: ( click the link to review the publication )

Toxicol Sci, 2015, 10.1093/toxsci/kfv056

PubMed: 25766884 ( click the link to review the publication )

Sci Rep, 2015, 5:13001

PubMed: 26306624 ( click the link to review the publication )

J Biol Chem, 2015, 290(50):29854-68

PubMed: 26483548 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(2):639-650

PubMed: ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 283(1):1-8

PubMed: 25576094 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 10.1016/j.taap.2015.03.018

PubMed: 25817892 ( click the link to review the publication )

Int J Oncol, 2015, 46(2):474-86

PubMed: 25422130 ( click the link to review the publication )
Phys Chem Chem Phys, 2015, 17(29):18971-9

PubMed: 26126833 ( click the link to review the publication )

Cell Signal, 2015, 27(10):1939-48

PubMed: 26163823 ( click the link to review the publication )

Int J Oncol, 2015, 46(2):474-86

PubMed: ( click the link to review the publication )

BMC Cancer, 2015, 15:738

PubMed: 26483043 ( click the link to review the publication )

BMC Cancer, 2015, 15:444

PubMed: 26025442 ( click the link to review the publication )

Toxicol In Vitro, 2015, 29(8):1965-76

PubMed: 26165741 ( click the link to review the publication )

Biomed Rep, 2015, 3(6):797-801

PubMed: 26623018 ( click the link to review the publication )

Biosci Rep, 2015, 35(6)

PubMed: 26500282 ( click the link to review the publication )

Malar J, 2015, 14(1):200

PubMed: 25968882 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0143847

PubMed: 26630652 ( click the link to review the publication )

PLoS One, 2015, 10(8):e0134825

PubMed: 26284517 ( click the link to review the publication )

Biomed Res Int, 2015, 2015:417586

PubMed: 26539491 ( click the link to review the publication )

Leuk Res, 2015, 10.1016/j.leukres.2015.08.007

PubMed: 26346348 ( click the link to review the publication )

Int J Hematol, 2015, 102(5):569-78

PubMed: 26341959 ( click the link to review the publication )

Anticancer Res, 2015, 35(12):6623-32

PubMed: 26637878 ( click the link to review the publication )

J Bio Mater Res, 2015, 103(4):1476-84

PubMed: ( click the link to review the publication )

Chem Biol, 2015, 10.1016/j.chembiol.2015.01.004

PubMed: 25728267 ( click the link to review the publication )

Oncotarget, 2015, 51: S659-S660

PubMed: ( click the link to review the publication )

Oncotarget, 2015, 6(10):8200-9

PubMed: 25860931 ( click the link to review the publication )

Oncotarget, 2015, 6(10):8418-29

PubMed: 25762625 ( click the link to review the publication )

Oncotarget, 2015, 6(22):18921-32

PubMed: 26254279 ( click the link to review the publication )

Oncotarget, 2015, 6(28):26347-58

PubMed: 26267322 ( click the link to review the publication )

Oncotarget, 2015, 6(35):38079-92

PubMed: 26472030 ( click the link to review the publication )

Oncotarget, 2015, 6(1):56-70

PubMed: 25474141 ( click the link to review the publication )
Sci Transl Med, 2014, 6(250):250ra112

PubMed: 25143362 ( click the link to review the publication )

Blood, 2014, 123(26):4120-31

PubMed: 24711662 ( click the link to review the publication )

J Clin Invest, 2014, 124(9):3757-66

PubMed: 25061876 ( click the link to review the publication )

Nat Commun, 2014, 5:3384

PubMed: 24594970 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(6):1576-89

PubMed: 24634471 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(16):E1591-9

PubMed: 24715725 ( click the link to review the publication )

Cancer Res, 2014, 74(16):4458-69

PubMed: 24934808 ( click the link to review the publication )

Cancer Res, 2014, 74(10):2803-15

PubMed: 24686171 ( click the link to review the publication )

Cancer Res, 2014, 74(11):3127-36

PubMed: 24755468 ( click the link to review the publication )

J Cell Biol, 2014, 205(6):771-80

PubMed: 24934156 ( click the link to review the publication )

Cell Death Differ, 2014, 21(12):1838-51

PubMed: 25034784 ( click the link to review the publication )

Mol Cancer, 2014, 13(1):159

PubMed: 24972933 ( click the link to review the publication )

Int J Cancer, 2014, 135(12):2950-61

PubMed: 24771510 ( click the link to review the publication )

Eur J Cancer, 2014, 51(1):1-8

PubMed: 25466507 ( click the link to review the publication )

Cancer Lett, 2014, 343(2):286-94

PubMed: 24120758 ( click the link to review the publication )

Br J Cancer, 2014, 110(9):2224-31

PubMed: 24691427 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1126

PubMed: 24625985 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1013

PubMed: 24457957 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1580

PubMed: 25522274 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(4):926-37

PubMed: 24482380 ( click the link to review the publication )

Br J Haematol, 2014, 167(5):639-50

PubMed: 25155625 ( click the link to review the publication )

J Biomed Nanotechnol, 2014, 10(4):717-23

PubMed: 24734524 ( click the link to review the publication )

J Biomed Nanotechnol, 2014, 10(4):717-23

PubMed: 24734524 ( click the link to review the publication )

J Am Heart Assoc, 2014, 3(1):e000520

PubMed: 24572252 ( click the link to review the publication )
J Nutr Biochem, 2014, 25(5):515-25

PubMed: 24613086 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt13):2898-909

PubMed: 24806960 ( click the link to review the publication )

J Virol, 2014, 87(23):13035-41

PubMed: 24027330 ( click the link to review the publication )

Eur J Immunol, 2014, 44(6):1604-14

PubMed: 24643698 ( click the link to review the publication )

J Leukocyte Biol, 2014, 95(3):461-9

PubMed: 24231258 ( click the link to review the publication )

Sci Rep, 2014, 4:4164

PubMed: 24566666 ( click the link to review the publication )

Sci Rep, 2014, 4:6370

PubMed: 25231679 ( click the link to review the publication )

Cancer Gene Ther, 2014, 21(11):472-82

PubMed: 25323693 ( click the link to review the publication )

J Biol Chem, 2014, 289(17):11906-15

PubMed: 24570003 ( click the link to review the publication )

J Biol Chem, 2014, 289(20):14075-88

PubMed: 24711452 ( click the link to review the publication )

J Biol Chem, 2014, 289(5):2687-700

PubMed: 24337575 ( click the link to review the publication )

J Proteome Res, 2014, 13(5):2223-38

PubMed: 24669782 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(19):3570-8

PubMed: 25022755 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2014, 307(9):C774-87

PubMed: 25143351 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(10):1350-7

PubMed: 25019382 ( click the link to review the publication )

World J Gastroenterol, 2014, 20(48):18207-15

PubMed: 25561788 ( click the link to review the publication )

J Biomed Mater Res A, 2014, 10.1002/jbm.a.35286

PubMed: 25046528 ( click the link to review the publication )

Hematol Oncol, 2014, 10.1002/hon.2179

PubMed: 25394177 ( click the link to review the publication )

Neurotoxicology, 2014, 42:33-48

PubMed: 24705302 ( click the link to review the publication )

J Vasc Interv Radiol, 2014, 25(12):1972-82

PubMed: 25439675 ( click the link to review the publication )

Cancer Chemoth Pharm, 2014, 73(1):69-77

PubMed: 24190701 ( click the link to review the publication )

Cancer Chemoth Pharm, 2014, 10.1007/s00280-014-2451-7

PubMed: 24842158 ( click the link to review the publication )

PLoS One, 2014, 9(9):e103015

PubMed: 25181509 ( click the link to review the publication )

PLoS One, 2014, 9(6):e99211

PubMed: 24911872 ( click the link to review the publication )
PLoS One, 2014, 9(3):e89848

PubMed: 24595136 ( click the link to review the publication )

PLoS One, 2014, 9(9):e107009

PubMed: 25255316 ( click the link to review the publication )

Mol Cell Biochem, 2014, 398(1-2):165-73

PubMed: 25292312 ( click the link to review the publication )

J Nanopart Res, 2014, 42:33-48

PubMed: http://link.springer.com/article/10.1007/s11051-01 ( click the link to review the publication )

Biosciences biotechnology research asia, 2014, 10.13005bbra.1309

PubMed: ( click the link to review the publication )

Sci Rep, 2014, 4:5896

PubMed: 25077633 ( click the link to review the publication )

Blood, 2013, 123(5):706-16

PubMed: 24319254 ( click the link to review the publication )

Hepatology, 2013, 57(2):625-36

PubMed: 22991197 ( click the link to review the publication )

Nat Chem Biol, 2013, 10(1):61-8

PubMed: 24292069 ( click the link to review the publication )

Nat Protoc, 2013, 8(6):1155-68

PubMed: 23702832 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(20):5591-601

PubMed: 24004671 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 110(9):3501-6

PubMed: 23382202 ( click the link to review the publication )

Cancer Res, 2013, 74(1):56-67

PubMed: 24310398 ( click the link to review the publication )

Cell Rep, 2013, 4(4):751-63

PubMed: 23954782 ( click the link to review the publication )

Mucosal Immunol, 2013, 7(4):857-68

PubMed: 24280938 ( click the link to review the publication )

Int J Cancer, 2013, 133(6):1357-67

PubMed: 23463417 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(6):R107

PubMed: 24207099 ( click the link to review the publication )

Br J Dermatol, 2013, 168(3):504-12

PubMed: 23445313 ( click the link to review the publication )

Free Rad Biol Med, 2013, 65:778-88

PubMed: 23973637 ( click the link to review the publication )

Exp Mol Med, 2013, 45:e50

PubMed: 24158003 ( click the link to review the publication )

Pain, 2013, 154(11):2432-40

PubMed: 23891899 ( click the link to review the publication )

Expert Opin Drug Deliv, 2013, 10(10):1345-52

PubMed: 23937147 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(7):1299-309

PubMed: 23657945 ( click the link to review the publication )

Mol Oncol, 2013, 7(6):1012-8

PubMed: 23916134 ( click the link to review the publication )
ACS Chem Biol, 2013, 8(3):578-87

PubMed: 23198928 ( click the link to review the publication )

Gynecol Oncol, 2013, 128(2):383-90

PubMed: 23107612 ( click the link to review the publication )

FEBS J, 2013, 280(15):3609-20

PubMed: 23702335 ( click the link to review the publication )

J Virol, 2013, 87(21):11872-83

PubMed: 23986594 ( click the link to review the publication )

Biochim Biophys Acta, 2013, 1830(10):4456-69

PubMed: 23742826 ( click the link to review the publication )

Biochem Pharmacol, 2013, 85(11):1611-8

PubMed: 23523860 ( click the link to review the publication )

Mol Cell Biol, 2013, 33(12):2375-87

PubMed: 23572559 ( click the link to review the publication )

J Trauma Acute Care Surg, 2013, 74(2):499-507

PubMed: 23354244 ( click the link to review the publication )

Mol Biol Cell, 2013, 35:215-22

PubMed: 24145151 ( click the link to review the publication )

Clin Exp Metastasis, 2013, 30(4):407-15

PubMed: 23412907 ( click the link to review the publication )

Retrovirology, 2013, 10(1):120

PubMed: 24156270 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2013, 139(9):1551-62

PubMed: 23877657 ( click the link to review the publication )

Toxicol Lett, 2013, 223(2):109-15

PubMed: 24055520 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 72(6):1335-42

PubMed: 24121478 ( click the link to review the publication )

PLoS One, 2013, 8(3):e59390

PubMed: 23527180 ( click the link to review the publication )

PLoS One, 2013, 8(9):e75280

PubMed: 24086494 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82053

PubMed: 24312627 ( click the link to review the publication )

Eur J Haematol, 2013, 91(4):339-46

PubMed: 23869695 ( click the link to review the publication )

Leuk Res, 2013, 37(10):1302-8

PubMed: 23896061 ( click the link to review the publication )

J Int Med Res, 2013, 41(5):1505-19

PubMed: 23975859 ( click the link to review the publication )

Curr Protoc Chem Biol, 2013, 5(3):195-212

PubMed: 24391083 ( click the link to review the publication )

Blood, 2012, 119(24):5772-81

PubMed: 22538852 ( click the link to review the publication )

Blood, 2012, 119(11):2579-89

PubMed: 22262760 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(17):4669-81

PubMed: 22806876 ( click the link to review the publication )
Br J Pharmacol, 2012, 168(8):1868-77

PubMed: 23194305 ( click the link to review the publication )

Cancer Lett, 2012, 316(1):77-84

PubMed: 22082529 ( click the link to review the publication )

J Invest Dermatol, 2012, 132(5):1487-96

PubMed: 22377766 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e295

PubMed: 22495350 ( click the link to review the publication )

FASEB J, 2012, 26(5):1855-65

PubMed: 22345405 ( click the link to review the publication )

Mol Cancer Ther, 2012, 11(11):2321-30

PubMed: 22964485 ( click the link to review the publication )

Mol Cancer Ther, 2012, 11(10):2243-53

PubMed: 22933706 ( click the link to review the publication )

Br J Haematol, 2012, 157(6):718-31

PubMed: 22533681 ( click the link to review the publication )

J Virol, 2012, 86(18):10112-22

PubMed: 22787216 ( click the link to review the publication )

J Virol, 2012, 86(24):13360-70

PubMed: 23015717 ( click the link to review the publication )

Am J Physiol Endocrinol Metab, 2012, 303(3):E410-21

PubMed: 22669242 ( click the link to review the publication )

J Biol Chem, 2012, 287(13):10344-54

PubMed: 22318734 ( click the link to review the publication )

J Biol Chem, 2012, 288(2):1125-34

PubMed: 23209294 ( click the link to review the publication )

J Biol Chem, 2012, 288(4):2721-33

PubMed: 23209292 ( click the link to review the publication )

J Biol Chem, 2012, 287(41):34722-9

PubMed: 22910913 ( click the link to review the publication )

J Pharmacol Exp Ther, 2012, 343(1):184-97

PubMed: 22787116 ( click the link to review the publication )

Prostate, 2012, 72(10):1140-9

PubMed: 22127954 ( click the link to review the publication )

Cell Cycle, 2012, 11(9):1804-17

PubMed: 22510564 ( click the link to review the publication )

BMC Cancer, 2012, 12:541

PubMed: 23171055 ( click the link to review the publication )

Biol Reprod, 2012, 87(2):44

PubMed: 22592496 ( click the link to review the publication )

PLoS One, 2012, 7(1):e29541

PubMed: 22235305 ( click the link to review the publication )

PLoS One, 2012, 7(4):e34684

PubMed: 22514654 ( click the link to review the publication )

Exp Mol Pathol, 2012, 93(1):99-110

PubMed: 22475623 ( click the link to review the publication )

Steroids, 2012, 77(11):1025-32

PubMed: 22683670 ( click the link to review the publication )
J Biomol Screen, 2012, 17(9):1231-42

PubMed: 22927676 ( click the link to review the publication )

J Biomol Screen, 2012, 17(5):572-80

PubMed: 22357874 ( click the link to review the publication )

Biochem Cell Biol, 2012, 90(2):224-31

PubMed: 22397456 ( click the link to review the publication )

Saint Louis University, 2012, 2012/0270829

PubMed: ( click the link to review the publication )

Sarcoma, 2012, 2012:805614

PubMed: 22919280 ( click the link to review the publication )

Blood, 2011, 118(14):3922-31

PubMed: 21841164 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(16):5311-21

PubMed: 21724551 ( click the link to review the publication )

Development, 2011, 138(14):2903-8

PubMed: 21653611 ( click the link to review the publication )

Br J Haematol, 2011, 155(5):588-98

PubMed: 21950728 ( click the link to review the publication )

J Biol Chem, 2011, 286(18):16018-29

PubMed: 21454483 ( click the link to review the publication )

Exp Cell Res, 2011, 317(18):2671-82

PubMed: 21871886 ( click the link to review the publication )

Int Immunopharmacol, 2011, 11(12):2242-5

PubMed: 21979495 ( click the link to review the publication )

PLoS One, 2011, 6(8):e23712

PubMed: 21887304 ( click the link to review the publication )

Cell Biochem Biophys, 2011, 60(3):173-85

PubMed: 21132543 ( click the link to review the publication )

University of Porto, 2011, Mireia Vila Gasull

PubMed: ( click the link to review the publication )

Glia, 2010, 58(16):1961-76

PubMed: 20830808 ( click the link to review the publication )

Carcinogenesis, 2010, 31(11):1948-55

PubMed: 20837598 ( click the link to review the publication )

J Virol, 2010, 84(18):9439-51

PubMed: 20592098 ( click the link to review the publication )

J Biol Chem, 2010, 285(52):41074-86

PubMed: 20956535 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with K_i of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.

Targets

20S proteasome ^[1]
(Cell-free assay)

0.6 nM(Ki)

In vitro

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. ^[2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. ^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
MCF-7	M3fLeGN6fG:2b4jpZ{BCe3OjeR?=	Mmq0OVAh\|ryP	M1vrcVQ5KGh?	MWjEUXNQ	NUixfWZ4U2mubIOgZ4VtdHNiYomgcY9z\SC2aHHuJFk6LQ>?	NVroc2FzOTB2OUm2OFM>
OVCA 429	M1ewbWZ2dmO2aX;uJGF{e2G7	M4fSTVMxOCCwTR?=	NVXEbHFHPDhiaB?=	MYHEUXNQ	NGHR[Y5FcXO{dYD0d{BqdnSjY4SgcZVtfGmlZXzseYxieiC2dX3vdkB{eGincn;p[JM>	M2q5e\|ExQTl7N{[2
RPMI8226	M1\CcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXGzSmpQOTByIH7N	M{XIcVQ5KGh?	NWPNb5c2TE2VTx?=	MU\JR\|UxRTNyIH7N	MnzxNVE{ODZ2OEm=
Dox40	NWHIUnNuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUmxNFAhdk1?	NX;VNHY6PDhiaB?=	NHfTWHRFVVOR	MlzTTWM2OD12MDDuUS=>	M3jBXlEyOzB4NEi5
MR20	MkLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmOzNVAxKG6P	Mlz4OFghcA>?	M4jBRWROW09?	M2W5bmlEPTB;MkCgcm0>	MXOxNVMxPjR6OR?=
LR5	NIj0RYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnv6NVAxKG6P	NF:xOZQ1QCCq	MoTjSG1UVw>?	MonkTWM2OD1{MDDuUS=>	NX;GO5lmOTF\|ME[0PFk>
U266	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWPhdVNVOTByIH7N	NYnUfWFnPDhiaB?=	M2jWNmROW09?	M3j3e2lEPTB;MzDuUS=>	M3TYRVEyOzB4NEi5
IM-9	M3vvWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFO3VHoyODBibl2=	M{jSNlQ5KGh?	MVnEUXNQ	MkXGTWM2OD14IH7N	MkDCNVE{ODZ2OEm=
Hs Sultan	NW\Ieok{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGKybmwyODBibl2=	NILTPY41QCCq	NIHpPZpFVVOR	MnrZTWM2OD1{MDDuUS=>	NVz2eJR3OTF\|ME[0PFk>
PAM-LY2	MWXGeY5kfGmxbjDBd5NigQ>?	MU[xNFAhdk1?	NGTvWXYyOiCq	MV7EUXNQ	Mn;TTY5pcWKrdIOgUmYu\|rqEIHHjeIl3[XSrb36=	MYWxNVM2ODlzMx?=
PAM 212	MomxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVyxNFAhdk1?	MlrHO\|IhcA>?	NHfxWJhFVVOR	NWnyUGlMUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm=	MVexNVM2ODlzMx?=
PAM-LY2	NH73VphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PlU\|ExOCCwTR?=	MmXaO\|IhcA>?	M1rF[WROW09?	Mo\HTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl?	MWOxNVM2ODlzMx?=
B4B8	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY[xNFAhdk1?	NWjBS41SPzJiaB?=	M4X5fWROW09?	Mk\vTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl?	MmG4NVE{PTB7MUO=
B7E3	M4TnTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1LWdlExOCCwTR?=	Mn3LO\|IhcA>?	Ml3qSG1UVw>?	M{DafGlvcGmkaYTzJINmdGxidnnhZoltcXS7	NGLIdWQyOTN3MEmxNy=>
UM-SCC-9	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXXXWXNLOTByIH7N	NWnpdoFCPzJiaB?=	NFjoNmdFVVOR	M361eGlvcGmkaYTzJINmdGxidnnhZoltcXS7	M3vGVVEyOzVyOUGz
UM-SCC-11B	M{XnbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYX1cJRFOTByIH7N	M3fSflczKGh?	Ml3GSG1UVw>?	M3T2U2lvcGmkaYTzJINmdGxidnnhZoltcXS7	NWXnR4pUOTF\|NUC5NVM>
H460	MoHPSpVv[3Srb36gRZN{[Xl?	NH\leo8yOCEQvF2=	NY\MXWpPOjRiaB?=	MYnEUXNQ	M4W0bWlv\HWlZYOgRoNtNTJicHjvd5Bpd3K7bHH0bY9vKGGwZDDjcIVifmGpZTDjc5Jz\WyjdHXkJJdqfGhiR{KtUUBxcGG\|ZTDhdpJme3R?	NXzHWpd6OTJ2OUKxNVc>
U266	NE\tdYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYe1NFAhdmdxbXy=	M3HJRlQ5KGh?	NXTqdoZzTE2VTx?=	MUXJcohq[mm2czDj[YxtKGe{b4f0bC=>	Mmf6NVI3OzF4MUm=
ARH77	NF7mRVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LCV\|UxOCCwZz;tcC=>	NIHKNHo1QCCq	MV7EUXNQ	M{jXNmlvcGmkaYTzJINmdGxiZ4Lve5Rp	M3v4VFEzPjNzNkG5
WAD-1	NEjWWFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXHTNVl2PTByIH7nM41t	M{jaS\|Q5KGh?	M4LzOmROW09?	NGm3ZYhKdmirYnn0d{Bk\WyuIHfyc5d1cA>?	MkizNVI3OzF4MUm=
U266/LR7	NG\zTWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4SwO\|UxOCCwZz;tcC=>	NIf2T241QCCq	MV;EUXNQ	NYfZPXI6UW6qaXLpeJMh[2WubDDndo94fGh?	NWLveYNNOTJ4M{G2NVk>
U266/dox4	MnPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHPzenY2ODBibnevcYw>	M2OzRlQ5KGh?	NGHPWpVFVVOR	NWLIZpRNUW6qaXLpeJMh[2WubDDndo94fGh?	NGjHSXQyOjZ\|MU[xPS=>
RPMI8226/LR5	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mof3OVAxKG6pL33s	NH;ETm01QCCq	NHHvdFFFVVOR	NWH5dopGUW6qaXLpeJMh[2WubDDndo94fGh?	MnzJNVI3OzF4MUm=
H460	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVixNEDPxE1?	MVi3NkBp	MljYSG1UVw>?	Ml\5TWM2OD1zMECgcm0>	NEO3O2syOjZ\|MU[yNC=>
H358	NYjjdIlQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnuxNVAh\|ryP	NIDFcG44OiCq	MXvEUXNQ	NHXqNI1KSzVyPUewJI5O	M1\2TlEzPjNzNkKw
H322	NWnnV5F1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV[xNEDPxE1?	NH7YXmE4OiCq	NYnHbWFjTE2VTx?=	NWTsXmdoUUN3ME22NlAhdk1?	MofpNVI3OzF4MkC=
H460	MVjGeY5kfGmxbjDBd5NigQ>?	MVWxNFAhdk1?	NEXPU2kzPCCq	Mn:xSG1UVw>?	MmSzTY5lfWOnczDHNk1ONXCqYYPlJIFzemW\|dDDhcoQhfHWkdXzpckBie3OnbXLsfU1lcXOjc4PlcYJtgQ>?	NEO0NYYyOjZ\|MU[yNC=>
LNCap-Pro5	M4XiUGZ2dmO2aX;uJGF{e2G7	MWCxJO69VQ>?	MoLLOEBp	M1KxZmROW09?	M4TxcXN1[WKrbHn6[ZMheDV\|	MXSxOFYyOjV\|Mh?=
T29	NVXteIJWSXCxcITvd4l{KEG\|c3H5	NX\PeZZnPTBibl2=	MnTuOFghcCB?	NH3a[pdFVVOR	NF;INW5KdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	M{HkZ\|E3Pzd6MUe5
T29Kt1	Mn3jRZBweHSxc3nzJGF{e2G7	MXO1NEBvVQ>?	NEHremY1QCCqIB?=	MnL5SG1UVw>?	NGX3bIRKdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	NXj5WIVDOTZ5N{ixO\|k>
HCT116	M1;vWmFxd3C2b4Ppd{BCe3OjeR?=	MljnOVAhdk1?	MYW0PEBpKA>?	NH\2eGpFVVOR	MULJcoR2[2W\|IHPlcIwh[XCxcITvd4l{	MXOxOlc4QDF5OR?=
HKe-3	NYrMR2pNSXCxcITvd4l{KEG\|c3H5	MkTrOVAhdk1?	M3HlUFQ5KGhi	NH3XfI1FVVOR	MkG3TY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	NV;aTmxZOTZ5N{ixO\|k>
NB-1691	MmXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37KdFEh\|ryP	NIXPbo04OiCq		NFOwfHBKdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hfG9iNTW=	MYqxO\|Y5QTZ6NB?=
CHLA-255	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnGxNUDPxE1?	NVvKSWczPzJiaB?=		MVTJcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36geI8hOiV?	NGTBSmoyPzZ6OU[4OC=>
SK-N-AS	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV2xJO69VQ>?	Mn;sO\|IhcA>?		M{DhWWlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckB1dyBzMDW=	NYDGN2s1OTd4OEm2PFQ>
NB-1691	MXLGeY5kfGmxbjDBd5NigQ>?	MY[xNEBvVQ>?	MXSyOEBp		NWnoXGczW2mpbnnmbYNidnSueTDy[YR2[2W\|IHPlcIx{KGmwIITo[UBIOC:JMTDwbIF{\Q>?	MV:xO\|Y5QTZ6NB?=
CHLA-255	M2nWSWZ2dmO2aX;uJGF{e2G7	NGnZWVkyOCCwTR?=	NWLGWWJSOjRiaB?=		M4TFNG1w\GW\|dHz5JJJm\HWlZYOgZ4VtdHNiaX6geIhmKEdyL1exJJBp[XOn	Mn7MNVc3QDl4OES=
RPMI 8226	MlrsSpVv[3Srb36gRZN{[Xl?	NWjrV\|BpOjBibl2=	M3PuXVghcA>?		MkWyV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk>	MnzPNVk1OzZyNUC=
MM.1S	MorGSpVv[3Srb36gRZN{[Xl?	NXvzXZJlOjBibl2=	M3rNdlghcA>?		M4HndnNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6	NX;XVodOOTl2M{[wOVA>
U266	MnrjSpVv[3Srb36gRZN{[Xl?	NX\PeXNrOjBibl2=	NGLBe2I5KGh?		NVHnTGU6W2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl?	M{HhelE6PDN4MEWw
OPM1	MonrSpVv[3Srb36gRZN{[Xl?	NXHheXFnOjBibl2=	NF\IZZk5KGh?		NGXucI9UcWewaX\pZ4FvfGy7IHXubIFv[2W\|IF7GMe67SiCjY4Tpeol1gQ>?	MVexPVQ{PjB3MB?=
INA6	NVeyblZiTnWwY4Tpc44hSXO\|YYm=	MWCyNEBvVQ>?	M{LYd\|ghcA>?		M1TjNnNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6	MmDiNVk1OzZyNUC=
OPM2	NHP1PZBHfW6ldHnvckBCe3OjeR?=	MYSyNEBvVQ>?	MX:4JIg>		M3;NZ3Nq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6	NIDEb3MyQTR\|NkC1NC=>
RPMI 8226	NWXtXohkTnWwY4Tpc44hSXO\|YYm=	M3e5XFIxKG6P	MlzpPEBp		NYrydo8yUW6mdXPld{BFVkFic4nueIhme2m\|	NVTRbIJSOTl2M{[wOVA>
BaF/3	NUO0SI41T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4PyV\|ExOCCwTR?=	NIPkTpk1QCCq		M3HhV2lEPTB;Nj6yJI5O	MlzjNlA{ODV4OUK=
BaF/3-p210	MonJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEnISWoyODBibl2=	M{mzXVQ5KGh?		NGLOdFhKSzVyPUSuO{BvVQ>?	NFjreJYzODNyNU[5Ni=>
TCC-S	NU\6V4hKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1u0VFExOCCwTR?=	Mn7EOFghcA>?		Mn\UTWM2OD1{Lkigcm0>	NH;BRpgzODNyNU[5Ni=>
BaF/3	NYntc\|lPTnWwY4Tpc44hSXO\|YYm=	MoTUOkBvVQ>?	MnvPOFghcA>?		NEnFc3dKdmS3Y3XzJIEh\3KnYYSgS\|Eh[2WubD3jfYNt\SCjcoLld5Q>	M3;nPFIxOzB3Nkmy
BaF/3-p210	NGnmSW9HfW6ldHnvckBCe3OjeR?=	MlfOOkBvVQ>?	MnXpOFghcA>?		MoPzTY5lfWOnczDhJJNtcWeqdDDHNUBk\WyuLXP5Z4xmKGG{cnXzeC=>	NXSxd49JOjB\|MEW2PVI>
BaF/3-p210	NH65PWpHfW6ldHnvckBCe3OjeR?=	NXfiSJR1PiCwTR?=	Mn[0NlQhcA>?		M4TPVnJm\HWlZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBidmRidHjlJIFkfGm4aYT5JI9nKFKk	NX3z[IRUOjB\|MEW2PVI>
Raji	MoD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1jv[lEh\|ryP	NFfzUZYzPCCq		NX;NbpNrWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg	M2XEXVIyOTdyOUi4
LCL-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{nQXlEh\|ryP	Mo\SNlQhcA>?		MXTS[YR2[2W\|IHPlcIwhfmmjYnnsbZR6yqB?	MmTRNlEyPzB7OEi=
LCL-2	M4S1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXuxJO69VQ>?	NVu0OVl3OjRiaB?=		MmnsVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi	M4rS[\|IyOTdyOUi4
BJAB	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH3UN5AyKM7:TR?=	Mle4NlQhcA>?		NUOz[mx{WmWmdXPld{Bk\WyuII\pZYJqdGm2edMg	M3vEcVIyOTdyOUi4
SNT-13	Mo\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYixJO69VQ>?	M{fwXlI1KGh?		M1;zeHJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?=	MlzjNlEyPzB7OEi=
SNT-16	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWP4e4pvOSEQvF2=	NX;NXWg3OjRiaB?=		NGT2fWhT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC=	MVGyNVE4ODl6OB?=
Jurkat	MlfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIm0eVMyKM7:TR?=	Ml[0NlQhcA>?		NWrjXm13WmWmdXPld{Bk\WyuII\pZYJqdGm2edMg	NVm2[pVGOjFzN{C5PFg>
KAI-3	NFjRcnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXzsTYN3OSEQvF2=	M3TZWFI1KGh?		M4Xqc3Jm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?=	NXjsSXZMOjFzN{C5PFg>
SNK-6	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF3lRVUyKM7:TR?=	MoHYNlQhcA>?		M{nXcnJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?=	M3nwTlIyOTdyOUi4
KHYG-1	MnvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjSNUDPxE1?	MojENlQhcA>?		MXrS[YR2[2W\|IHPlcIwhfmmjYnnsbZR6yqB?	NXK5WGJlOjFzN{C5PFg>
SNT-16	MWLBdI9xfG:\|aYOgRZN{[Xl?	MlXyNUDPxE1?	MkWzOkBp		NFnkSpRKdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	M33qRVIyOTdyOUi4
Jurkat	NFzFZ49CeG:ydH;zbZMhSXO\|YYm=	NELEcYsyKM7:TR?=	MnTnOkBp		NHvKTGVKdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	MoCzNlEyPzB7OEi=
KAI-3	NVf4[lZYSXCxcITvd4l{KEG\|c3H5	M373eFEh\|ryP	M1vh[VYhcA>?		MYPJcoR2[2W\|IHPlcIwh[XCxcITvd4l{	NFHrd5czOTF5MEm4PC=>
KHYG-1	MmqyRZBweHSxc3nzJGF{e2G7	M3XYU\|Eh\|ryP	NYGwNIkxPiCq		M13ROmlv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	MV6yNVE4ODl6OB?=
SNT-13	NHHQbnRCdnSrdnnyZYwhSXO\|YYm=	NV3kSpNGOSEQvF2=	NXPsbYduOjRiaB?=		NH\CfY1KdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ?	MX:yNVE4ODl6OB?=
SNT-16	M4XacmFvfGm4aYLhcEBCe3OjeR?=	NX[5RotqOSEQvF2=	MorvNlQhcA>?		MnnHTY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJX	M2mzUlIyOTdyOUi4
KAI-3	MkjyRY51cX[rcnHsJGF{e2G7	NYjoXlJGOSEQvF2=	NXnhXG9LOjRiaB?=		MYTJcoR2[2W\|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY>	NFzob5YzOTF5MEm4PC=>
SNK-6	NW\2ZmVkSW62aY\pdoFtKEG\|c3H5	MkPMNUDPxE1?	MmfCNlQhcA>?		NVKwVmhxUW6mdXPld{BtgXSrYzDpcoZm[3Srb36gc4YhTUKY	MoTvNlEyPzB7OEi=
RAW 264.7	M{GzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWexNFAhdk1?	NV;Cb3lpPDhiaB?=		M4LtZ3Jm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?=	NFzsd3UzOjR{N{G1OC=>
A375	MUjBdI9xfG:\|aYOgRZN{[Xl?	MWixNEBvVQ>?	NXHSeIFvOjRiaB?=		MlPZTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	MXGyN\|A4QTB6Mx?=
BLM	MmHqRZBweHSxc3nzJGF{e2G7	Mn:5NVAhdk1?	NGTlV4YzPCCq		MYrJcoR2[2W\|IHPlcIwh[XCxcITvd4l{	MV2yN\|A4QTB6Mx?=
A375	NGfSNlNCfXSxcHjh[5khSXO\|YYm=	NXTpTlB4OTBibl2=	MkD6NVIhcA>?		MVjJcoR2[2W\|IH\vdo1ifGmxbjDv[kBifXSxcHjh[49{d22ncx?=	MmHaNlMxPzlyOEO=
BLM	MWLBeZRweGijZ4mgRZN{[Xl?	M37PfFExKG6P	M1nQN\|EzKGh?		MU\JcoR2[2W\|IH\vdo1ifGmxbjDv[kBifXSxcHjh[49{d22ncx?=	NH;6TGgzOzB5OUC4Ny=>
H1299	NEXiW4hCeG:ydH;zbZMhSXO\|YYm=	M2ftPVgxKG6P	MnnTNlQhcA>?	Mn;uSG1UVw>?	Mnn2V4Vve2m2aYrld{BPW0OOQzDj[YxteyC2bzDNV2Mu\GW{aY\l[EBqSzlvaX7keYNm\CCjcH;weI9{cXN?	NEDpdI0zPTN{M{[5Ny=>
Hut-78	MnnNSpVv[3Srb36gRZN{[Xl?	MYixNFAhdk1?	MmHRNlQhcA>?	Mnq0SG1UVw>?	M1;3fGRwf26{ZXf1cIF1\XNiVFfGMe6zOSCjbnSgTWwuOTBiZYjwdoV{e2mxbh?=	MUGyOVY5OTN\|NR?=
H9	NUPwOIEyTnWwY4Tpc44hSXO\|YYm=	NIHLc5QyODBibl2=	Mme2NlQhcA>?	NWK4bVltTE2VTx?=	MWDEc5dvemWpdXzheIV{KFSJRj5OtlEh[W6mIFnMMVEyKGW6cILld5Nqd25?	MVOyOVY5OTN\|NR?=
HH	M{TKVGZ2dmO2aX;uJGF{e2G7	Mme4NVAxKG6P	Ml3UNlQhcA>?	NFzMdoFFVVOR	NUe1WXR{\G:5boLl[5Vt[XSnczDUS2Yu\|rJzIHHu[EBKVC1zMjDlfJBz\XO\|aX;u	NV7tZ2NZOjV4OEGzN\|U>
Hut-78	M1\ZZW1q\3KjdHnvckBCe3OjeR?=	M4nGRVExOCCwTR?=	Mn\JNlQhcA>?	NHfGRYpFVVOR	NImwXHNT\WS3Y3XzJINmdGxibXnndoF1cW:wIHL5JFgx6oDVOUCl	M1rDT\|I2PjhzM{O1
HH	M33PWW1q\3KjdHnvckBCe3OjeR?=	M4TnO\|ExOCCwTR?=	NI\0OJIzPCCq	M1ThRWROW09?	NXfuUI83WmWmdXPld{Bk\WyuIH3p[5JifGmxbjDifUA5OOLCk{mxKS=>	MkfGNlU3QDF\|M{W=
U937	NEm2V4VHfW6ldHnvckBCe3OjeR?=	MX6xNFAhdk1?	NY\BTG9mPiCq		M2qxO2lv\HWlZYOgTWwuQCCneIDy[ZN{cW:wIHnuJGxRWy2\|dHnteYxifGWmIGW5N\|chdWGlcn;wbIFo\XN?	MV2yOVc6OTR5Nx?=
human PBMC	Mn;3SpVv[3Srb36gRZN{[Xl?	MY[xNFAhdk1?	NXvhcJpVOjRiaB?=		M1jNfmlv\HWlZYOgTWwuQCC{ZXzlZZNm	NVv0NlJiOjV5OUG0O\|c>
ES6	MoHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3S0N2lEPTB;MD6wNFIyKG6P	NHTuU4pUSU6JRWK=
SK-UT-1	NF;oNotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2nOU2lEPTB;MD6xOlMhdk1?	MX7TRW5ITVJ?
SH-4	M3[yPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH65R21KSzVyPUCuNVc{KG6P	M4C5ZnNCVkeHUh?=
TE-9	M1vuSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFTDVXZKSzVyPUCuNVgzKG6P	NF\yVmhUSU6JRWK=
A253	NHPqfFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{Tic2lEPTB;MD6yNFghdk1?	NYP1WJBCW0GQR1XS
no-10	NVradnI3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1jOdGlEPTB;MD6yNUBvVQ>?	NVjJO2ZyW0GQR1XS
MMAC-SF	NFr2eFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX;JR\|UxRTBwMkG2JI5O	MYTTRW5ITVJ?
A101D	NFK2UGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUP3S2tCUUN3ME2wMlIzPSCwTR?=	MVfTRW5ITVJ?
NTERA-S-cl-D1	NEn4RmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkfvTWM2OD1yLkK0N{BvVQ>?	NE\kbmxUSU6JRWK=
8-MG-BA	NHTGOW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn3ZTWM2OD1yLkK1JI5O	MnfjV2FPT0WU
KNS-42	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M174[GlEPTB;MD6yOVghdk1?	NVzTS25NW0GQR1XS
LXF-289	NIHwe\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTBwMk[5JI5O	M2DIfXNCVkeHUh?=
OVCAR-4	NF2wV41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnjNTWM2OD1yLkK4PUBvVQ>?	MoK2V2FPT0WU
LOUCY	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTBwMkmzJI5O	M{D6cnNCVkeHUh?=
BB65-RCC	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF6yXYtKSzVyPUCuN\|A1KG6P	MonvV2FPT0WU
D-542MG	M3TVPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGDHdnlKSzVyPUCuN\|I6KG6P	MV3TRW5ITVJ?
ONS-76	M{C4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mk[wTWM2OD1yLkOzJI5O	M3GxXnNCVkeHUh?=
BB30-HNC	NWDvVVVVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUHjOI5iUUN3ME2wMlM{PSCwTR?=	NGXnd\|dUSU6JRWK=
KS-1	NWjmWWhyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDlTWM2OD1yLkO0JI5O	MYfTRW5ITVJ?
A388	NGDKUZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M37wZmlEPTB;MD6zOVYhdk1?	NFnFTHlUSU6JRWK=
ES8	M{Czd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWPJR\|UxRTBwNDDuUS=>	MonhV2FPT0WU
MZ2-MEL	NV7DOFNRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmfFTWM2OD1yLkSwO{BvVQ>?	MYHTRW5ITVJ?
HCC2998	MoPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXS1bYR2UUN3ME2wMlQyOiCwTR?=	MnPwV2FPT0WU
D-247MG	NITXXWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\UcI5KSzVyPUCuOFE{KG6P	NH\S[phUSU6JRWK=
ACN	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWXCeIJOUUN3ME2wMlQyPyCwTR?=	NYX4ZmtqW0GQR1XS
LB2518-MEL	NHzEeWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1;nfWlEPTB;MD60NlUhdk1?	MWXTRW5ITVJ?
ES1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4jOSWlEPTB;MD60N{BvVQ>?	MmjUV2FPT0WU
HCE-T	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV;JR\|UxRTBwNEO5JI5O	NEX5dVlUSU6JRWK=
OS-RC-2	NHHoNG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFz3U2RKSzVyPUCuOFQhdk1?	MYTTRW5ITVJ?
MFH-ino	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRTBwNESzJI5O	MkLuV2FPT0WU
OCUB-M	NFjTbndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVv4cHlzUUN3ME2wMlQ1PyCwTR?=	M2\MdXNCVkeHUh?=
CP66-MEL	Mm\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnnpTWM2OD1yLkS3N{BvVQ>?	MXPTRW5ITVJ?
LB771-HNC	NE\6XYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{nITmlEPTB;MD60O\|Qhdk1?	MVLTRW5ITVJ?
DSH1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXvJR\|UxRTBwNEigcm0>	NF;2T2tUSU6JRWK=
HUTU-80	M4TsfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M37wfGlEPTB;MD61N\|Mhdk1?	Mn6wV2FPT0WU
CESS	NYPRcWNQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUC5[pI2UUN3ME2wMlU{QCCwTR?=	M33BOHNCVkeHUh?=
NCI-H747	NEH6[4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml\UTWM2OD1yLkWzPUBvVQ>?	NVrtUJM5W0GQR1XS
HT-144	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYHGNldTUUN3ME2wMlU4PiCwTR?=	MlL4V2FPT0WU
COLO-829	M2DOe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mln2TWM2OD1yLk[xOEBvVQ>?	MnzEV2FPT0WU
A4-Fuk	NWfi[4xZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnHwTWM2OD1yLk[yN{BvVQ>?	NGnVSoNUSU6JRWK=
GI-ME-N	NXPSS5VmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF\5VXhKSzVyPUCuOlM1KG6P	NHHrOVRUSU6JRWK=
LB831-BLC	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTBwNkSxJI5O	M2fjWXNCVkeHUh?=
HOP-62	M1vzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4\sRmlEPTB;MD62OFchdk1?	M4H6VnNCVkeHUh?=
BB49-HNC	NGS0eWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\5TWM2OD1yLk[1NkBvVQ>?	MYLTRW5ITVJ?
D-336MG	NHjjW3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NULLV\|VJUUN3ME2wMlY2PyCwTR?=	NYfBVHRHW0GQR1XS
TK10	MnHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mkj1TWM2OD1yLk[3PUBvVQ>?	NFTPW3VUSU6JRWK=
Ramos-2G6-4C10	NWr1fXBUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXTDeXZpUUN3ME2wMlY6OyCwTR?=	NV3YZ\|FoW0GQR1XS
LB373-MEL-D	NVvpVG1JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1;jWWlEPTB;MD63JI5O	NFXQTJdUSU6JRWK=
SF126	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTBwN{CxJI5O	M3mxW3NCVkeHUh?=
UACC-257	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXzJR\|UxRTBwN{Ggcm0>	M1zBNXNCVkeHUh?=
KINGS-1	NHnVNW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVKyWmcyUUN3ME2wMlczOiCwTR?=	NFzmcXVUSU6JRWK=
LS-513	NYPIRpJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{j6eWlEPTB;MD63N\|khdk1?	M4XDeHNCVkeHUh?=
GI-1	NUW3S3dUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUm5TXhoUUN3ME2wMlc3PCCwTR?=	NFrPeYtUSU6JRWK=
ES7	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEe1PHdKSzVyPUCuO\|Y3KG6P	NIHGblJUSU6JRWK=
LB2241-RCC	NWLnVXZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoHWTWM2OD1yLkiwOEBvVQ>?	MYnTRW5ITVJ?
D-263MG	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3\BcGlEPTB;MD64NFchdk1?	MXTTRW5ITVJ?
SW684	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWD6N\|F4UUN3ME2wMlgzOSCwTR?=	MVPTRW5ITVJ?
ML-2	M3LlN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV;kNVlxUUN3ME2wMlgzOSCwTR?=	NYTGTYdpW0GQR1XS
SK-LMS-1	NWjrc453T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnT4TWM2OD1yLki1OEBvVQ>?	MVzTRW5ITVJ?
TE-5	M3K2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2\tSGlEPTB;MD64OlUhdk1?	NWDRbYdKW0GQR1XS
QIMR-WIL	NXXyRm42T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NE\Xc3FKSzVyPUCuPFg6KG6P	NH;LbVVUSU6JRWK=
NCI-H1355	M2LBWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUDKdJBtUUN3ME2wMlg6PSCwTR?=	M2XwenNCVkeHUh?=
SNB75	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVX4cIZiUUN3ME2wMlkyOiCwTR?=	MWDTRW5ITVJ?
RXF393	NF3YTVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVjPboVkUUN3ME2wMlkyPCCwTR?=	MXPTRW5ITVJ?
IST-MEL1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3HJRWlEPTB;MD65NVchdk1?	NWLCNI8{W0GQR1XS
SF268	M4nmdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYm1SXNSUUN3ME2wMlkzOyCwTR?=	MV;TRW5ITVJ?
KALS-1	M3jOSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NY\XfG5SUUN3ME2wMlkzPSCwTR?=	M4PSc3NCVkeHUh?=
HC-1	MmS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEe1WWVKSzVyPUCuPVc2KG6P	MYTTRW5ITVJ?
SW872	MknYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTBwOUm2JI5O	NES0XHpUSU6JRWK=
PSN1	M4D6Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTFwMEGgcm0>	MoP2V2FPT0WU
TE-1	NX3XV2FRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3rySGlEPTB;MT6wN{BvVQ>?	NXHEUZpsW0GQR1XS
TE-10	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF\iRWlKSzVyPUGuNFMhdk1?	MYHTRW5ITVJ?
RKO	NIKyfZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHfSeG9KSzVyPUGuNFYhdk1?	MUTTRW5ITVJ?
LC-2-ad	MojNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF2z[2hKSzVyPUGuNFghdk1?	NXr5Rm5UW0GQR1XS
SK-MM-2	NXj1UFk5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTFwMEmgcm0>	M3;OPHNCVkeHUh?=
VA-ES-BJ	NWTjVYRrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{PUcGlEPTB;MT6wPUBvVQ>?	MoPCV2FPT0WU
MZ7-mel	M2i2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFTzTI1KSzVyPUGuNFkhdk1?	NE\weXZUSU6JRWK=
D-392MG	M4DQcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnXXTWM2OD1zLkGgcm0>	NEe5cIdUSU6JRWK=
CCRF-CEM	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTFwMUOgcm0>	Mn7NV2FPT0WU
EM-2	Ml23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX\JR\|UxRTFwMU[gcm0>	MVXTRW5ITVJ?
HAL-01	NX;n[\|hPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWTye5ZKUUN3ME2xMlE5KG6P	M1XlcXNCVkeHUh?=
TE-8	NVX2WFl3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF3HeGJKSzVyPUGuNVkhdk1?	NHj2NphUSU6JRWK=
NCI-H1882	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV\SSoxyUUN3ME2xMlIhdk1?	NWr6ZpJIW0GQR1XS
Daudi	MlfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnIcZhKSzVyPUGuNlIhdk1?	NHnwd5RUSU6JRWK=
BL-41	NVvibIxXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHj2fWlKSzVyPUGuNlUhdk1?	MoXhV2FPT0WU
SR	NID0[3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTFwMkWgcm0>	MVjTRW5ITVJ?
KM12	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFu4WnVKSzVyPUGuNlchdk1?	NUHUUI52W0GQR1XS
K5	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX3JR\|UxRTFwMkigcm0>	NG\wbWxUSU6JRWK=
A3-KAW	Mo\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGnQ[XdKSzVyPUGuNlghdk1?	NILnXWJUSU6JRWK=
CMK	MlrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjJR\|UxRTFwMkmgcm0>	NUCxfWptW0GQR1XS
Calu-6	M2\1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHHXR4xKSzVyPUGuNlkhdk1?	NWHPcoJjW0GQR1XS
IST-SL2	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1TFZmlEPTB;MT6zNUBvVQ>?	MWPTRW5ITVJ?
OPM-2	M4KwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoDGTWM2OD1zLkOzJI5O	M{LZb3NCVkeHUh?=
DU-4475	NYflOGdLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnTQTWM2OD1zLkO2JI5O	M1G4dXNCVkeHUh?=
ECC12	Mn7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\ySlhKSzVyPUGuN\|chdk1?	MYLTRW5ITVJ?
L-540	MnnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1PqZ2lEPTB;MT6zO{BvVQ>?	MnL3V2FPT0WU
CAS-1	NUnTSHFZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MknDTWM2OD1zLkO3JI5O	MlL3V2FPT0WU
PF-382	NXPrRVgzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1LTZmlEPTB;MT60O{BvVQ>?	NIL0N\|FUSU6JRWK=
LS-411N	M3;aOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX75WGZDUUN3ME2xMlU{KG6P	MoHsV2FPT0WU
NCI-H69	M1vXdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH3KOIpKSzVyPUGuOVQhdk1?	Mn7OV2FPT0WU
NB12	M2HJbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHziWVhKSzVyPUGuOVYhdk1?	MofkV2FPT0WU
HEL	M3vVemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2jxSGlEPTB;MT62NUBvVQ>?	MWDTRW5ITVJ?
GCIY	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIHSVIZKSzVyPUGuOlIhdk1?	MYDTRW5ITVJ?
EHEB	NEDNWWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml30TWM2OD1zLk[3JI5O	MUPTRW5ITVJ?
TGBC1TKB	M4PMc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWSyb4N[UUN3ME2xMlcyKG6P	NVzUOGFWW0GQR1XS
KURAMOCHI	NIW2V4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2PrbGlEPTB;MT63NkBvVQ>?	MlfjV2FPT0WU
U-266	M2SxN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4PoWGlEPTB;MT63OkBvVQ>?	NHjGUHRUSU6JRWK=
LC4-1	NITT[\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlPxTWM2OD1zLke5JI5O	NUXmboNXW0GQR1XS
NCI-H2126	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEXQWJdKSzVyPUGuPEBvVQ>?	MV7TRW5ITVJ?
NCI-H1092	NEi4PVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTFwODDuUS=>	NH\q[pJUSU6JRWK=
GB-1	NVribWxVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWjJR\|UxRTFwOEGgcm0>	MX;TRW5ITVJ?
MV-4-11	MoLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml;HTWM2OD1zLkiyJI5O	NH6xWWZUSU6JRWK=
Becker	NUXY[JlVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVXJR\|UxRTFwOEOgcm0>	Mnq2V2FPT0WU
MPP-89	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1\0Z2lEPTB;MT64PUBvVQ>?	MlzUV2FPT0WU
BE-13	NIfNUWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{CyUmlEPTB;MT65N{BvVQ>?	NGLTS4NUSU6JRWK=
697	NEG1S\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTFwOUmgcm0>	MVvTRW5ITVJ?
NKM-1	MnnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjJR\|UxRTJibl2=	MYDTRW5ITVJ?
NB13	NFL3WFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYm0d\|RVUUN3ME2yJI5O	MXfTRW5ITVJ?
LS-123	MlfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFLySo1KSzVyPUKuNFIhdk1?	MmHYV2FPT0WU
NB17	MlrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFrPbnZKSzVyPUKuNFQhdk1?	NGPoVGxUSU6JRWK=
LAN-6	M1nLOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVLpc\|JoUUN3ME2yMlA2KG6P	NVPPV3RFW0GQR1XS
EW-24	MmjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXnhXllKUUN3ME2yMlA5KG6P	M3HTe3NCVkeHUh?=
NOS-1	M4iwdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4m2PWlEPTB;Mj6xNUBvVQ>?	MYnTRW5ITVJ?
BL-70	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWntdG9PUUN3ME2yMlEzKG6P	NEXHRWtUSU6JRWK=
GT3TKB	M3vJSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVPwepAxUUN3ME2yMlEzKG6P	NGDCNVBUSU6JRWK=
HH	NHXiSplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoPWTWM2OD1{LkGzJI5O	MnK0V2FPT0WU
KE-37	Mo\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUPJR\|UxRTJwMUOgcm0>	NH7EOmdUSU6JRWK=
MOLT-4	NFfJRoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm[0TWM2OD1{LkGzJI5O	NXTXS2ozW0GQR1XS
EKVX	NGfBXGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTJwMUSgcm0>	MnLyV2FPT0WU
KGN	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX;nbYE{UUN3ME2yMlE2KG6P	MXHTRW5ITVJ?
ES4	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4nSRWlEPTB;Mj6xOkBvVQ>?	M13nXnNCVkeHUh?=
SJSA-1	M1r4V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;MTWM2OD1{LkKxJI5O	MlPTV2FPT0WU
KMOE-2	M3:ybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTJwMkOgcm0>	NE\we21USU6JRWK=
NB5	M4jaTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlzLTWM2OD1{LkK3JI5O	NEHzR2hUSU6JRWK=
BC-1	MmHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV3icmFDUUN3ME2yMlMyKG6P	NWjJWppyW0GQR1XS
NB10	NGrDU2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX32eXllUUN3ME2yMlMzKG6P	M{jwN3NCVkeHUh?=
RPMI-8226	NGLXUXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX;JR\|UxRTJwM{Wgcm0>	MmToV2FPT0WU
SCC-3	NVnjO5FZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFe2OY5KSzVyPUKuN\|chdk1?	M{jne3NCVkeHUh?=
ARH-77	MnjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3vYdWlEPTB;Mj6zPEBvVQ>?	NWnueWlbW0GQR1XS
NCI-H748	NVfUSI5lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M37BXGlEPTB;Mj6zPUBvVQ>?	NHPFO2tUSU6JRWK=
KU812	NHvFUGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE[3O4RKSzVyPUKuOFIhdk1?	NVPVe3lUW0GQR1XS
NCI-H64	NGDOUlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MojUTWM2OD1{LkS0JI5O	NVG4NHhpW0GQR1XS
NB69	M3GyWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEOyfIVKSzVyPUKuOFYhdk1?	NITrcHFUSU6JRWK=
KNS-81-FD	MmK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVvQfZMzUUN3ME2yMlQ5KG6P	Ml3hV2FPT0WU
LB1047-RCC	M1XPZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTJwNUegcm0>	NEnLXVRUSU6JRWK=
EB-3	M{K5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;jTWM2OD1{Lk[2JI5O	MWDTRW5ITVJ?
Mo-T	MlXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGLjUWdKSzVyPUKuO\|Qhdk1?	NGK5XmlUSU6JRWK=
EW-16	NVv0W2tlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1nBO2lEPTB;Mj63OUBvVQ>?	MmfYV2FPT0WU
CTV-1	MkO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRTJwODDuUS=>	MX7TRW5ITVJ?
ETK-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPJR\|UxRTJwOESgcm0>	NF;jO2FUSU6JRWK=
C2BBe1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUnJR\|UxRTJwOEmgcm0>	Mo\5V2FPT0WU
MOLT-16	NFnHVJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlLmTWM2OD1{Lki5JI5O	MoXFV2FPT0WU
SW954	MkXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1;3VGlEPTB;Mj65JI5O	NEjn[Y9USU6JRWK=
HT	NXHqeJRRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVP6[XdKUUN3ME2zMlAzKG6P	NVu3WnRUW0GQR1XS
KARPAS-299	NUjHR2h4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTNwME[gcm0>	MofmV2FPT0WU
MONO-MAC-6	M{TyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVjZ[m4xUUN3ME2zMlEhdk1?	NYOzVJhEW0GQR1XS
CGTH-W-1	Mmf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHJR\|UxRTNwMTDuUS=>	NWnBN2N1W0GQR1XS
SK-PN-DW	NHfj[HFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1jRTGlEPTB;Mz6xOEBvVQ>?	NG\tc3hUSU6JRWK=
CW-2	NXzQeFh{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{nGT2lEPTB;Mz6yNUBvVQ>?	M1njc3NCVkeHUh?=
SK-N-DZ	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn3RTWM2OD1\|LkK2JI5O	M4fZVXNCVkeHUh?=
NEC8	M1vRZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXfPc28xUUN3ME2zMlM2KG6P	NUPpeVVQW0GQR1XS
LB996-RCC	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmjKTWM2OD1\|LkSgcm0>	MlrXV2FPT0WU
DB	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXjJR\|UxRTNwNEGgcm0>	MljyV2FPT0WU
TE-15	M4Pq[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4HPSWlEPTB;Mz60N{BvVQ>?	NXv3WHgxW0GQR1XS
COR-L88	M4D2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkLWTWM2OD1\|LkS3JI5O	Ml;2V2FPT0WU
LAMA-84	NVPaW3hRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRTNwNEmgcm0>	MkXUV2FPT0WU
MEG-01	M1fHUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWjUVpgxUUN3ME2zMlQ6KG6P	MVzTRW5ITVJ?
LOXIMVI	NY[wZ2U5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4\2T2lEPTB;Mz61JI5O	MYPTRW5ITVJ?
RPMI-8402	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEPNTlVKSzVyPUOuOUBvVQ>?	NWC3PHVzW0GQR1XS
KARPAS-45	MlT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYXIeXpyUUN3ME2zMlU1KG6P	NG\NNW5USU6JRWK=
HCC1187	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYHJR\|UxRTNwNUSgcm0>	Mm\HV2FPT0WU
MZ1-PC	M4e4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPJR\|UxRTNwNUSgcm0>	NUDvN2NpW0GQR1XS
no-11	NHqw[VFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mme3TWM2OD1\|LkW1JI5O	MUXTRW5ITVJ?
EVSA-T	Mnj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFP1eVRKSzVyPUOuOkBvVQ>?	MVvTRW5ITVJ?
DJM-1	NH7pXVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFezS2FKSzVyPUOuOlMhdk1?	MmPiV2FPT0WU
COLO-684	M4XaTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoizTWM2OD1\|Lk[2JI5O	NF;lPZNUSU6JRWK=
NMC-G1	NYPF[IQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mnj6TWM2OD1\|Lk[4JI5O	NYXLVYtSW0GQR1XS
LC-1F	NXPYbpBxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEmxOYRKSzVyPUOuO\|Qhdk1?	NEfuS\|lUSU6JRWK=
RL95-2	M3vxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUfQZ4tRUUN3ME2zMlc6KG6P	MlK0V2FPT0WU
COLO-320-HSR	NGXGbodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYjkXmx7UUN3ME2zMlkzKG6P	MUjTRW5ITVJ?
RCC10RGB	M12wUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYW3SpNmUUN3ME2zMlk{KG6P	NV3RbWV7W0GQR1XS
HD-MY-Z	M4fFO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUjtNpI{UUN3ME2zMlk{KG6P	MmDYV2FPT0WU
NCI-H2141	M4PJeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3OyVGlEPTB;ND6wOUBvVQ>?	M1y0dXNCVkeHUh?=
K-562	M33rTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M17jWWlEPTB;ND6xNkBvVQ>?	NXXlS2VkW0GQR1XS
NCI-H1648	NVLK[G91T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnXGTWM2OD12LkGzJI5O	MYTTRW5ITVJ?
OMC-1	NHHldHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUnTNHRDUUN3ME20MlE5KG6P	MmDqV2FPT0WU
LB647-SCLC	NHLDPYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NID1dJRKSzVyPUSuNlIhdk1?	MY\TRW5ITVJ?
TE-12	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUm3PZdrUUN3ME20MlI2KG6P	M{e4d3NCVkeHUh?=
NOMO-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnzrTWM2OD12LkOzJI5O	MVfTRW5ITVJ?
Raji	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUXxb4ZqUUN3ME20MlQ3KG6P	NVL6ZXJLW0GQR1XS
NALM-6	M2LESGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFfGcFJKSzVyPUSuOFkhdk1?	MlfWV2FPT0WU
HL-60	MoLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3e3XGlEPTB;ND62O{BvVQ>?	MYTTRW5ITVJ?
IST-SL1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlKxTWM2OD12Lk[4JI5O	NVnudIltW0GQR1XS
MHH-PREB-1	Mk\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4OzU2lEPTB;ND64OkBvVQ>?	MWPTRW5ITVJ?
MHH-NB-11	NYjE[o1UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVPRdVlGUUN3ME20MlkyKG6P	MnPmV2FPT0WU
JiyoyeP-2003	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYDz[4pIUUN3ME21JI5O	NXLabYFvW0GQR1XS
SBC-1	NXvlSItUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXHnZZJmUUN3ME21MlAyKG6P	M4jDVnNCVkeHUh?=
CHP-126	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWfUPIJLUUN3ME21MlA3KG6P	MYrTRW5ITVJ?
LU-139	NYe4SWZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGL4PW9KSzVyPUWuNVMhdk1?	MXHTRW5ITVJ?
NCI-SNU-5	NIjlPGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGO3VWVKSzVyPUWuNVchdk1?	MUnTRW5ITVJ?
SW962	M2XLbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NELEfnNKSzVyPUWuNlEhdk1?	NUHCNlJDW0GQR1XS
EW-1	Mmf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmHRTWM2OD13LkOxJI5O	NXPNfHc3W0GQR1XS
NCI-H1417	M3X2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2[0b2lEPTB;NT61NUBvVQ>?	Ml74V2FPT0WU
LU-65	MlH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIm5dHFKSzVyPUWuPFQhdk1?	NXi3dlVuW0GQR1XS
D-502MG	MlXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4HwcGlEPTB;Nj6zO{BvVQ>?	NVHH[JVMW0GQR1XS
BC-3	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTZwNkGgcm0>	Mn3sV2FPT0WU
GDM-1	M1K0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI\4e4ZKSzVyPU[uO\|chdk1?	MWfTRW5ITVJ?
NCI-H2196	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\sO2JKSzVyPU[uPEBvVQ>?	MoXrV2FPT0WU
NB1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1zyeWlEPTB;Nj64PEBvVQ>?	NXfpSFZKW0GQR1XS
NCI-H345	M1;RWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\wW5hRUUN3ME23MlIhdk1?	NULvV\|VbW0GQR1XS
SU-DHL-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXjYRVdZUUN3ME23MlI1KG6P	MnPGV2FPT0WU
JVM-2	MnzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3zGfWlEPTB;Nz6yPEBvVQ>?	MYHTRW5ITVJ?
LU-134-A	NUnVdFNsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{O3e2lEPTB;Nz6zPUBvVQ>?	NVfGS3d5W0GQR1XS
NCI-H1694	NY\sZlJrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlH2TWM2OD15LkW4JI5O	M4nZVnNCVkeHUh?=
NCI-SNU-16	MnrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX[wcY5UUUN3ME23MlY2KG6P	MV;TRW5ITVJ?
L-363	M2fLbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnPxTWM2OD15Lkegcm0>	M4[wPHNCVkeHUh?=
KG-1	MlTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFmxWJRKSzVyPUeuPVQhdk1?	MWnTRW5ITVJ?
MN-60	NFrvVYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXXBRo5JUUN3ME24MlE1KG6P	MXfTRW5ITVJ?
NB6	M3njdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUjJR\|UxRThwNEigcm0>	M1XZc3NCVkeHUh?=
MLMA	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUHoZ5I4UUN3ME24Mlg2KG6P	MlzMV2FPT0WU
ATN-1	NUDlcHdDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4XUUmlEPTB;OD64PUBvVQ>?	NHnDTWNUSU6JRWK=
SK-NEP-1	NGXHdWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXrqUHQ{UUN3ME25MlAyKG6P	MXnTRW5ITVJ?
DMS-114	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkflTWM2OD17Lk[yJI5O	M2Lh[HNCVkeHUh?=
CTB-1	M2XBPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTlwNkegcm0>	NYPtZldvW0GQR1XS
NCI-H2081	MnLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFHDfndKSzVyPUGwMlA6KG6P	NWDlbIZSW0GQR1XS
ES5	MmrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkfyTWM2OD1zMD6zPEBvVQ>?	M2fTOXNCVkeHUh?=
HCC1599	MnmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFvOOZhKSzVyPUGxMlkyKG6P	Mof3V2FPT0WU
NCI-H23	M4LETWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MofXTWM2OD1zMj6xNkBvVQ>?	NITIdGVUSU6JRWK=
NCI-H1581	M4fiSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTF{LkK4JI5O	M2nad3NCVkeHUh?=
JVM-3	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1vzSmlEPTB;MUKuPVkhdk1?	MkH2V2FPT0WU
NCI-SNU-1	NHfjOpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlfWTWM2OD1zMz6xPUBvVQ>?	NHjOSm5USU6JRWK=
NB7	NHTWTWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlHzTWM2OD1zNT65NkBvVQ>?	MkTGV2FPT0WU
JAR	NXi1epA1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIPYTmNKSzVyPUG2MlE{KG6P	MVHTRW5ITVJ?
TGW	M1W0bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWP5[WZ5UUN3ME2xOk41QCCwTR?=	MlKyV2FPT0WU
U-87-MG	M4PWfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MW\JR\|UxRTF4Lke2JI5O	NHu5cJhUSU6JRWK=
NCI-H1436	MmT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTF5LkCxJI5O	M1nSW3NCVkeHUh?=
GOTO	M2DXdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2\qWGlEPTB;MUeuNFYhdk1?	NU\BU5BrW0GQR1XS
COLO-800	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEPiVXNKSzVyPUG3MlY1KG6P	NHjhVGhUSU6JRWK=
MFM-223	MkLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MofITWM2OD1zNz65NUBvVQ>?	M1znTnNCVkeHUh?=
EW-18	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkjPTWM2OD1zNz65OkBvVQ>?	NXXIbpdYW0GQR1XS
NB14	NUfrUpRqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4\XUGlEPTB;MUeuPVghdk1?	NHfTZXlUSU6JRWK=
EB2	MmezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEG2Tm9KSzVyPUG4MlA5KG6P	NXnrZXlMW0GQR1XS
EoL-1-	NHfVZllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV:x[Ic2UUN3ME2xPE4{OSCwTR?=	MWPTRW5ITVJ?
NCCIT	MnyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlLLTWM2OD1zOD6zOkBvVQ>?	M2r5V3NCVkeHUh?=
DG-75	M4i0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE\FV2RKSzVyPUG4MlYyKG6P	M1TocnNCVkeHUh?=
HCC2218	NFjFc3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1ywTWlEPTB;MUmuOUBvVQ>?	NWLWUlJXW0GQR1XS
TE-6	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnfNTWM2OD1{MD6wPEBvVQ>?	MUfTRW5ITVJ?
SF539	NUnJXohHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUn4OZRwUUN3ME2yNE43PyCwTR?=	MVPTRW5ITVJ?
NCI-H446	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF\DT\|BKSzVyPUKxMlE5KG6P	NWTm[WZWW0GQR1XS
IST-MES1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnewTWM2OD1{Mj63O{BvVQ>?	M2P0cHNCVkeHUh?=
NCI-H82	M1rzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;NSpJKSzVyPUKzMlAzKG6P	NFWzT4FUSU6JRWK=
HCC2157	M2T6UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1[wcWlEPTB;MkOuNVMhdk1?	M{Lsb3NCVkeHUh?=
EW-12	M3mxT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{\QUGlEPTB;MkOuNVchdk1?	M2f0N3NCVkeHUh?=
SIMA	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVjMWXgyUUN3ME2yN{4{QCCwTR?=	NHjEOHpUSU6JRWK=
DOHH-2	NWm0RpdqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnJR\|UxRTJ\|LkS1JI5O	MV7TRW5ITVJ?
IM-9	NEXkbYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF3LfYJKSzVyPUKzMlU1KG6P	MUTTRW5ITVJ?
EC-GI-10	NWHxW4dOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYPJR\|UxRTJ2LkKzJI5O	NH;sZnZUSU6JRWK=
HDLM-2	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTJ2LkW0JI5O	M3;3OXNCVkeHUh?=
LS-1034	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4[wU2lEPTB;MkWuO\|Uhdk1?	MXHTRW5ITVJ?
REH	MmjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHTBd41KSzVyPUK2MlQyKG6P	M2\6SXNCVkeHUh?=
LU-165	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4rO[2lEPTB;Mk[uO\|Ihdk1?	MYPTRW5ITVJ?
NH-12	M{naT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXXwS5Z4UUN3ME2yO{43PyCwTR?=	MVfTRW5ITVJ?
WSU-NHL	NHOzVJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTJ6LkO5JI5O	NYPw[ldLW0GQR1XS
ECC4	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2D1bWlEPTB;MkiuO\|khdk1?	NGHoZo9USU6JRWK=
OCI-AML2	NXPEUohbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTJ7Lk[5JI5O	NUHJPGNPW0GQR1XS
EW-3	NVvFcpVRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGjI[YtKSzVyPUOwMlU6KG6P	NGjnNHdUSU6JRWK=
NCI-H526	M{\FfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXftc3d[UUN3ME2zNk42PCCwTR?=	MofJV2FPT0WU
NCI-H719	NI\ETYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXL0[WZ2UUN3ME2zOE4{OSCwTR?=	MXjTRW5ITVJ?
KARPAS-422	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYK5RpFGUUN3ME2zOU4xPCCwTR?=	MmHkV2FPT0WU
SK-MEL-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYrtSFRyUUN3ME2zOU4yPyCwTR?=	Ml3MV2FPT0WU
ES3	M3T4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTN3LkG5JI5O	NV3MNJZ{W0GQR1XS
UACC-812	NUe0T4pmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M37pSmlEPTB;M{WuOFQhdk1?	NF7iVIpUSU6JRWK=
C8166	M2i2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4m5dGlEPTB;M{WuO{BvVQ>?	NHfoemNUSU6JRWK=
MDA-MB-134-VI	NWrifVFFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXnJR\|UxRTN3Lki3JI5O	MlTlV2FPT0WU
D-283MED	MoGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1\2cGlEPTB;M{euO\|khdk1?	M4DMb3NCVkeHUh?=
SHP-77	MnnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{HBZ2lEPTB;M{iuNFMhdk1?	M3:4cnNCVkeHUh?=
NCI-H2227	NYfz[HhIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEPEN4VKSzVyPUSwMlQ6KG6P	MmnPV2FPT0WU
SKM-1	Mo\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHnNZotKSzVyPUSyMlY{KG6P	MoD3V2FPT0WU
L-428	M3vjNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRTR\|Lki2JI5O	NHP6[4RUSU6JRWK=
RPMI-6666	MmPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4XncmlEPTB;NEWuPFkhdk1?	MnHIV2FPT0WU
NCI-H716	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoXETWM2OD12OD64NUBvVQ>?	MXXTRW5ITVJ?
DMS-79	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml\HTWM2OD13MD63NUBvVQ>?	M1nPV3NCVkeHUh?=
RS4-11	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH7XXoVKSzVyPUWwMlg5KG6P	M2rXbHNCVkeHUh?=
NCI-H720	M1jjVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4P4dmlEPTB;NUGuNVEhdk1?	NIHBZoVUSU6JRWK=
MC-CAR	M3;tZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M37sVWlEPTB;NUGuOVIhdk1?	MVnTRW5ITVJ?
TALL-1	NYPNS3FXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1;Zd2lEPTB;NUOuPVEhdk1?	NGH2cJJUSU6JRWK=
NCI-N87	NV;EVlBxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1\x[GlEPTB;NUSuNVghdk1?	MXPTRW5ITVJ?
P30-OHK	NYC4NG9KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX6xPItVUUN3ME21OE43OSCwTR?=	MmDSV2FPT0WU
LP-1	NFzPbGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnnTTWM2OD14MT6yPEBvVQ>?	NEDhXJZUSU6JRWK=
YT	NFXDTYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUDRTIduUUN3ME22NU45KG6P	NI\vcG5USU6JRWK=
MRK-nu-1	NGHkT5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3viZ2lEPTB;NkGuPFIhdk1?	MWfTRW5ITVJ?
BT-474	NHzPPIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmLSTWM2OD14NTDuUS=>	NYTlWVRIW0GQR1XS
NCI-H322M	Mn7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Moe1TWM2OD14Nj6xNUBvVQ>?	NGjRbWdUSU6JRWK=
NCI-H128	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHHFR25KSzVyPUe0Mlc4KG6P	MnPpV2FPT0WU
KMS-12-PE	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV\sdmo2UUN3ME23Ok4zPCCwTR?=	MlywV2FPT0WU
KP-N-YS	MknSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnPQTWM2OD15Nj63OEBvVQ>?	M3jHNXNCVkeHUh?=
ALL-PO	M1WyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTd5Lk[2JI5O	M2XhVnNCVkeHUh?=
EW-13	M{TR[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{frXmlEPTB;N{euO\|Yhdk1?	M3f4NXNCVkeHUh?=
EW-11	NFvVXFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnrVTWM2OD15OD61NkBvVQ>?	M2f1cnNCVkeHUh?=
SK-N-FI	NHrUSodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYH2TG9EUUN3ME24NE4zKG6P	NG\2TlNUSU6JRWK=
CAL-148	MonLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3rCS2lEPTB;OEGuPFQhdk1?	MY\TRW5ITVJ?
RL	NWHacnQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGDFUYhKSzVyPUi2MlA6KG6P	Mk[xV2FPT0WU
AM-38	NYniNZRiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX7uZ29MUUN3ME24PE4xQCCwTR?=	NFjjOmNUSU6JRWK=
RH-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1nZbmlEPTB;OUmuPFUhdk1?	NX;YTmFNW0GQR1XS
NCI-H1770	M3;ofWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTFyMj60PUBvVQ>?	MXjTRW5ITVJ?
SIG-M5	Mnf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUPJR\|UxRTFyNT6wOkBvVQ>?	NXjNZ3J6W0GQR1XS
GR-ST	M37KeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWTmNJFQUUN3ME2xNVMvOzRibl2=	MVLTRW5ITVJ?
ST486	NX22TnNzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWnJR\|UxRTFzND6wOkBvVQ>?	NI\FSo1USU6JRWK=
NCI-H1650	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXnlcHVRUUN3ME2xNVUvOjlibl2=	NV61ZZBpW0GQR1XS
MHH-CALL-2	NWLm[ZhuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV7JR\|UxRTFzNT63JI5O	MUfTRW5ITVJ?
BV-173	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTF{Mj63NUBvVQ>?	NXvkcXZ5W0GQR1XS
MC116	Mnm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWTmRZlwUUN3ME2xOFgvQDVibl2=	NEXPeHNUSU6JRWK=
NCI-H524	MmrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4XZR2lEPTB;MUW5MlEhdk1?	MUPTRW5ITVJ?
SCLC-21H	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXXNU4RpUUN3ME2xOVkvPDFibl2=	NX\qZ5c4W0GQR1XS
NCI-H1304	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo\NTWM2OD1zNkmuNlEhdk1?	NGjaVmtUSU6JRWK=
NCI-H510A	NG\PToRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGPXXnFKSzVyPUG4OU4{PyCwTR?=	MmC1V2FPT0WU
NCI-H209	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3yyWmlEPTB;MUm2MlUzKG6P	NEDnVpFUSU6JRWK=
KM-H2	M2i3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRTF7Nz6wOUBvVQ>?	M3fMR3NCVkeHUh?=
NCI-H1395	M1\Ve2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnLVTWM2OD1{MUCuNVMhdk1?	M2fJT3NCVkeHUh?=
NCI-H1155	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVjBRYdNUUN3ME2yN\|AvOzJibl2=	NUHaN4VLW0GQR1XS
COR-L279	M1\PSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoHZTWM2OD1{NUKuNVchdk1?	M2fmRnNCVkeHUh?=
NCI-H1299	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml3KTWM2OD1{NkGuO\|Ehdk1?	NHnVbo5USU6JRWK=
EW-22	MmfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV7JR\|UxRTJ4Mz63OUBvVQ>?	MoPkV2FPT0WU
SK-MEL-2	MnnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHnWVnNKSzVyPUK4NU46KG6P	M{OxV3NCVkeHUh?=
KASUMI-1	M4C1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFzkUZFKSzVyPUK4N{4xPSCwTR?=	M2P1d3NCVkeHUh?=
NCI-H187	M1roNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWrXPZYzUUN3ME2yPFcvODhibl2=	NV7ROpRwW0GQR1XS
NCI-H2171	Mm\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUPJR\|UxRTJ6OD65NkBvVQ>?	M2nsWHNCVkeHUh?=
LNCaP-Clone-FGC	NIH4RZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTJ7NT6yOkBvVQ>?	Mn\lV2FPT0WU
NCI-H1522	M4XVcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4S4W2lEPTB;M{C3MlA2KG6P	M33jPHNCVkeHUh?=
SCH	MlPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGrQNnVKSzVyPUOyNk4zOiCwTR?=	NWT3dWhVW0GQR1XS
THP-1	MomyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmDCTWM2OD1\|MkKuOkBvVQ>?	M{fETnNCVkeHUh?=
SNU-C1	MnTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTN4Mj6wPUBvVQ>?	NGnM[3ZUSU6JRWK=
CA46	M4nWVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTN5Mz62N{BvVQ>?	NX:yZYlQW0GQR1XS
NCI-H1963	Mli0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2L5bGlEPTB;M{i2MlE6KG6P	MV3TRW5ITVJ?
DEL	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlzvTWM2OD1\|OUGuNlchdk1?	NWW3N3hwW0GQR1XS
TUR	MoH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3rWRWlEPTB;M{m2MlYyKG6P	M3XNWHNCVkeHUh?=
NCI-H226	NG\Ub3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3LMbmlEPTB;NECzMlI{KG6P	NGfQTXFUSU6JRWK=
COLO-668	NIK5e3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWH2ToZNUUN3ME20NFMvPTdibl2=	NE[xe2VUSU6JRWK=
CPC-N	NF\6WoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW\lenpuUUN3ME20NFMvPzdibl2=	NXX3SmlyW0GQR1XS
NCI-H889	NGjvdWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYHScZdWUUN3ME20OlEvQTJibl2=	NVPXfHN1W0GQR1XS
J-RT3-T3-5	NUfWUmtqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXzwN4dHUUN3ME21N\|IvPTdibl2=	NXWyZmc4W0GQR1XS
MSTO-211H	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGewWZNKSzVyPUW3OE4zPiCwTR?=	NVmxXoZLW0GQR1XS
SCC-15	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{\LSWlEPTB;Nk[3MlQ4KG6P	MYfTRW5ITVJ?
SUP-T1	NF3P[oNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGTwVnlKSzVyPU[4Ok4xPCCwTR?=	NI\FTFBUSU6JRWK=
DMS-153	Mn;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI\Fd5lKSzVyPUe0Ok45OyCwTR?=	NYq4NIQ4W0GQR1XS
MS-1	NHfaN5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF7DPWFKSzVyPUe1PU41OiCwTR?=	MkTsV2FPT0WU
TC-YIK	NUTOcmM6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NULWfIhYUUN3ME23PFEvODFibl2=	M3\EPHNCVkeHUh?=
RPMI-8866	M2rFSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1HGeGlEPTB;MUCwOk4zQCEQvF2=	M1nM[XNCVkeHUh?=
KY821	M3X0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NETHSXZKSzVyPUGwN\|YvODRizszN	M3jDZ3NCVkeHUh?=
P31-FUJ	MnfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{Dl[mlEPTB;MUGxNk44PSEQvF2=	MXTTRW5ITVJ?
COLO-824	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3HCZWlEPTB;MUK2NU44QCEQvF2=	M3ntNHNCVkeHUh?=
U-698-M	MlTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWjpb5hxUUN3ME2yNlYzNjF3IN88US=>	NFvtU3ZUSU6JRWK=
TE-441-T	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1vOWmlEPTB;MkWyNU44KM7:TR?=	NXjafGhkW0GQR1XS
IMR-5	NVLIbWhXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFv5WGJKSzVyPUO0NFkvPjJizszN	NEPuUYVUSU6JRWK=
NCI-H1838	NYqxS5NRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4HrXGlEPTB;NEG4Ok4{OiEQvF2=	MWHTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	phospho-PERK / ATF-4; PubMed: 15509775 Mol Cell Biol UMSCC-23 cells were treated with PS-341 for the indicated time periods and concentrations. Whole-cell extracts were prepared, and 50-μg aliquots of proteins were probed with polyclonal antibodies against phospho-PERK, ATF-4. For loading control, the membranes were stripped and reprobed with monoclonal antibodies against α-tubulin. GRP-78 / GADD-34; PubMed: 15509775 Mol Cell Biol UMSCC-23 cells were treated with PS-341 for the indicated time periods and concentrations. Whole-cell extracts were prepared, and 50-μg aliquots of proteins were probed with polyclonal antibodies against GRP-78, and GADD-34. For loading control, the membranes were stripped and reprobed with monoclonal antibodies against α-tubulin. pro-caspase-12 / pro-caspase-3; PubMed: 15509775 Mol Cell Biol MEFs were treated with PS-341 for the indicated time periods, and the whole-cell extracts were prepared. Fifty-microgram aliquots of proteins were probed with polyclonal antibodies against caspase 12 and caspase 3. For loading control, the membrane was stripped and reprobed with monoclonal antibodies against α-tubulin. pro-caspase-9; PubMed: 15509775 Mol Cell Biol UMSCC-23 cells were pretreated with or without Tiron for 30 min and then treated with PS-341 for the indicated time periods. The whole-cell proteins were probed with polyclonal antibodies against caspases 9 and 3. For loading control, the membrane was stripped and reprobed with monoclonal antibodies against α-tubulin. p-IκBα / IκBα; PubMed: 20335171 J Biol Chem PS-341 induces IκBα degradation in human lung cancer cells. The given cells lines were treated with the indicated concentrations of PS-341 for 8 h (C). After treatment, the cells were then subjected to preparation of whole-cell protein lysates and subsequent Western blot analysis. COX-2 / cIAP2; PubMed: 24085292 J Biol Chem NCI-H157 cells were incubated with PS-341 (50 nM) or MG132 (20 μM) for the indicated times. Total cellular extracts were subjected to Western blot analysis for COX-2, cIAP2 and actin.	15509775 20335171 24085292
Immunofluorescence	Vimentin; PubMed: 19010849 Clin Cancer Res ES-2 ovarian cancer cells were incubated with 5nM PS-341, 10 μM NK84 or the combination of both for 24 hours before fixation and immuno-fluorescent staining of DNA (blue), ubiquitin (green) and vimentin (red) and imaging (X60 objective). Ubiquitin; PubMed: 19010849 Clin Cancer Res IOSE-29 cells were incubated with 20nM PS-341 for 24 hours before fixation and immuno-fluorescent staining of DNA (blue), ubiquitin (green) and vimentin (red) and imaging (X60 objective).	19010849
Growth inhibition assay	Cell viability ; PubMed: 20571067 Mol Cancer Ther A, TSA enhanced the cell death induced by PS-341 in UMSCC1 cells. Cell viability was determined by the trypan blue exclusion assay. The assays were performed with triplicate samples, and the results are representative of three independent experiments (P < 0.01). Error bars depict standard deviation. B, C and D, TSA enhanced PS-341-induced cell death in UMSCC23 (B), UMSCC9 (C), and FaDu (D). P < 0.01.	20571067
ELISA	IL-8; PubMed: 24085292 J Biol Chem NCI-H157 cells were treated with PS-341 (10–100 nm) or TNF-α (10 ng/ml) as a positive control for 24 h. IL-8 concentrations in media were determined by ELISA. Data represent the mean ± S.D. of triplicates. **, p < 0.05 versus control cells. Results are representative of three separate experiments.	24085292

In vivo

The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. ^[2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. ^[3]

Protocol

Kinase Assay: ^[4]	- Collapse Kinetic Methods: In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λ_ex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
Cell Research: ^[5]	- Collapse Cell lines: Human multiple myeloma cells line U266 Concentrations: ~10 μM Incubation Time: 2 days Method: The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer. (Only for Reference)
Animal Research: ^[3]	- Collapse Animal Models: Human plasmacytoma xenografts RPMI 8226 Formulation: Saline Dosages: 1 mg/kg Administration: i.v. twice weekly for 4 weeks, then once weekly (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	76 mg/mL (197.79 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Bortezomib (PS-341) SDF

Molecular Weight	384.24
Formula	C₁₉H₂₅BN₄O₄
CAS No.	179324-69-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	LDP-341, MLM341

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03993262	Not yet recruiting	Drug: Bortezomib\|Drug: Placebo	Autoimmune Encephalitis	Jena University Hospital	October 1 2019	Phase 2
NCT00425503	Completed	Drug: PS-341 (bortezomib)	Prostate Neoplasms	Baylor College of Medicine\|Millennium Pharmaceuticals Inc.	December 2001	Phase 2
NCT00025376	Completed	Drug: PS-341\|Procedure: Tumor Biopsy	Kidney Cancer	University of Chicago\|National Cancer Institute (NCI)	October 2001	Phase 2
NCT00237627	Completed	Drug: PS-341\|Drug: Doxil\|Drug: Velcade	Breast Cancer\|Leukemia\|Lymphoma\|Multiple Myeloma and Plasma Cell Neoplasm\|Ovarian Cancer\|Unspecified Adult Solid Tumor Protocol Specific	UNC Lineberger Comprehensive Cancer Center\|National Cancer Institute (NCI)	May 2001	Phase 1\|Phase 2
NCT00006773	Terminated	Drug: bortezomib	Adult Anaplastic Astrocytoma\|Adult Anaplastic Oligodendroglioma\|Adult Giant Cell Glioblastoma\|Adult Glioblastoma\|Adult Gliosarcoma\|Recurrent Adult Brain Tumor	National Cancer Institute (NCI)	May 2001	Phase 1
NCT00373906	Completed	Drug: Bortezomib (Velcade)	MALT Lymphoma	Medical University of Vienna		Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?
Answer:
S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Pan Proteasome Inhibitor

Ixazomib (MLN2238) : β5 site, IC50=3.4 nM; β1 site, IC50=31 nM; β2 site, IC50=3500 nM.
FDA-approved Proteasome Inhibitor

Carfilzomib (PR-171) : Approved by FDA for multiple myeloma.
Newest Proteasome Inhibitor

Oprozomib (ONX 0912) : Orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM.

Related Proteasome Products

VR23 ^New

VR23 is a potent proteasome inhibitor with IC50 of 1 nM, 50-100 nM, and 3 μM for trypsin-like proteasomes, chymotrypsin-like proteasomes, and caspase-like proteasomes, respectively.
Calpeptin ^New

Calpeptin is a potent, cell-permeable calpain inhibitor with ID50 of 52 nM, 34 nM, 138 nM, and 40 nM for Calpain I (porcine erythrocytes), Calpain II (porcine kidney), Papainb, and Calpain I (human platelets), respectively.
Marimastat (BB-2516) ^New

Marimastat (BB-2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 with IC50 of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. Phase 3.
MG-132

MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.
Carfilzomib (PR-171)

Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities.
Ixazomib (MLN2238)

MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and K_i of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. Phase 3.

Features:A first-in-class proteasome inhibitor that has improved pharmacokinetics (PK), pharmacodynamics(PD), and antitumor activity in preclinical studies.
Ixazomib Citrate (MLN9708)

Ixazomib Citrate (MLN9708) immediately hydrolyzed to MLN2238, the biologically active form, on exposure to aqueous solutions or plasma. MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/K_i of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Phase 3.

Features:The 1st oral proteasome inhibitor in early stage clinical trials for Multiple Myeloma.
Celastrol

Celastrol is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM.

Features:A potent antioxidant and anti-inflammatory drug.
Oprozomib (ONX 0912)

Oprozomib (ONX 0912) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM. Phase 1/2.

Choose Your Country or Region

By Signaling Pathways

By product type

Bortezomib (PS-341)

Cited by 379 Publications

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Bortezomib (PS-341) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Related Proteasome Products

Choose Your Country or Region

By Signaling Pathways

By product type

Bortezomib (PS-341)

Cited by 379 Publications

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Bortezomib (PS-341) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Related Proteasome Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)